

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 14/47, C12N 15/12, C07K 14/47, 16/18, A61K 38/17	A2	(11) International Publication Number: WO 98/18822 (43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/US97/18717 (22) International Filing Date: 10 October 1997 (10.10.97) (30) Priority Data: 08/739,485 28 October 1996 (28.10.96) US (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GOLI, Surya, K. [IN/US]; 620 Iris Avenue #338, Sunnyvale, CA 94086 (US). HILL-MAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). (74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).		(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: NOVEL HUMAN LIM PROTEINS (57) Abstract <p>The present invention provides three human LIM proteins (designated individually as HLIM-1, HLIM-2, and HLIM-3, and collectively as HLIM) and polynucleotides which identify and encode HLIM. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HLIM and a method for producing HLIM. The invention also provides for use of HLIM and agonists, antibodies, or antagonists specifically binding HLIM, in the prevention and treatment of diseases associated with expression of HLIM. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HLIM for the treatment of diseases associated with the expression of HLIM. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HLIM.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NOVEL HUMAN LIM PROTEINS

TECHNICAL FIELD

5 This invention relates to nucleic acid and amino acid sequences of novel human LIM proteins and to the use of these sequences in the diagnosis, prevention, and treatment of disease.

BACKGROUND ART

The LIM domain is a cysteine-rich motif which was first defined in the proteins Lin-
10 11 from C. elegans (Freyd, G. et al. (1990) Nature 344:876-879), insulin gene enhancer binding protein ISL1 from rat (Karlsson, O. et al. (1990) Nature 344:879-882), and Mec-3 from C. elegans (Way, J.C. et al. (1988) Cell 54:5-16). The name LIM is derived from the first letter of the names of these three proteins.

The sequence of the LIM domain is highly conserved among proteins found in
15 different tissues and across a variety of species, which is an indication of the functional importance of this domain (Sanchez-Garcia, I. et al. (1994) Trends Genet. 10:315-320). Two main classes of LIM proteins are known. One class consists of proteins that, like Lin-11, ISL1 and Mec-3, contain two LIM domains plus a homeodomain and are thus designated LIM-HD proteins. The second class of LIM proteins consists of one or more LIM domains
20 without a homeodomain and are thus designated "LIM-only" proteins.

A LIM domain is defined by the consensus amino acid sequence C-X₂-C-X₍₁₇₋₁₉₎-H-X₂-C-X₂-C-X₂-C-X₍₁₆₋₂₀₎-C-X₂-[C, H, or D] (Wang, X. et al. (1992) J. Biol. Chem. 267:9176-9184). The domain consists of two adjacent zinc-finger motifs. Two zinc ions bind to a LIM
25 domain, one per zinc finger. LIM domains function as protein-binding interfaces (Schmeichel, K.L. et al. (1994) Cell 79:211-219) and thus may act as cofactors in cell signaling.

Some LIM proteins exhibit oncogenic activity while other members of this diverse group may act as tumor suppressor molecules. The rhombotin genes (RBTN1 and RBTN2) encode LIM proteins which have been implicated in the control of the neoplastic phenotype.
30 RBTN2, identified in childhood T cell acute lymphoblastic leukemia (Boehm, T. et al. (1988) EMBO J. 7:385-394), is essential for erythroid cell development. A homozygous null

5 mutation in RBTN2 results in failure of yolk sac erythropoiesis and embryonic death (Warren, A.J. et al. (1994) Cell 78:45-57). In transgenic mice, cell-specific overexpression of RBTN1 or RBTN2 results in the generation of acute lymphoblastic lymphomas at low frequency (Fisch, P. et al. (1992) Oncogene 7:2389-2397; McGuire, E.A. et al. (1992) Mol. Cell Biol. 12:4186-4196).

10 Human cysteine-rich protein (CRP) is widely expressed in a variety of tissues. Its expression is induced shortly after serum stimulation of fibroblasts in the G₀ growth-arrest phase of the cell cycle. The serum induction kinetics of CRP closely parallel those of the *c-myc* oncogene, which suggests that these two genes respond to the same regulatory pathways and may share transcription control features (Wang et al, supra). CRP is thus proposed to be
15 a primary response gene induced as the cell transits from G₀ to G₁ or progresses from the S phase of the cell cycle, and is proposed to act as an oncogene.

Muscle LIM proteins (MLP) are involved in regulating cell-specific gene expression in heart and skeletal muscle. The expression of human MLP and the *Drosophila* homolog DMLP1 coincide with the differentiation of myoblasts into muscle cells. Overexpression of
20 MLP in C2 myoblasts potentiates myogenic cell differentiation, whereas expression of antisense MLP RNA retards myoblast differentiation (Arber, S. et al. (1994) Cell 79:221-231).

Smooth muscle LIM protein (smLIM) from rat is expressed preferentially in aortic smooth muscle cells. Like MLP, it is a developmentally regulated nuclear protein. SmLIM
25 mRNA levels decrease in vivo in response to vessel wall injury during periods of maximal smooth muscle proliferation (Jain, M.K. et al. (1996) J. Biol. Chem. 271:10194-10199).

Reversion-induced LIM (RIL) protein from rat is highly expressed in fibroblasts and is down-regulated in *H-ras* transformed cells. Expression of RIL is restored in phenotypic revertants derived from *H-ras* transformed cells. RIL is thus proposed to be involved in the
30 maintenance of normal cell growth (Kiess, M. et al. (1995) Oncogene 10:61-68). RIL is expressed in brain, heart, testes and variety of epithelia. The pattern of RIL protein expression suggests a physiological function in epithelial cells and in postmitotic neurons of the brain.

CLP36 protein is highly expressed in normal rat hepatocytes and is down-regulated in hypoxic hepatocytes. The relationship of this down-regulation to hypoxic injury is not

5 understood. CLP36 is found in a wide variety of tissues, at high abundance in heart, lung and liver, moderate abundance in spleen and skeletal muscle, and at extremely low abundance in testis and brain (Wang H. et al. (1995) Gene 165:267-271).

The discovery of polynucleotides encoding LIM proteins, and the protein molecules themselves, presents the opportunity to investigate physiological processes relating to the control of cellular differentiation, proliferation, and response to tissue injury. Discovery of
10 novel LIM proteins and the polynucleotides encoding them satisfies a need in the art by providing new diagnostic or therapeutic compositions directed toward diseases relating to cell damage and abnormal cell growth and proliferation such as arteriosclerosis and cancer.

DISCLOSURE OF THE INVENTION

15 The present invention features three novel human LIM proteins, designated individually as HLIM-1, HLIM-2 and HLIM-3 and collectively as HLIM, and characterized as having similarity to the LIM proteins CRP and MLP from human and smLIM, CLP36 and RIL from rat.

Accordingly, the invention features substantially purified HLIM proteins HLIM-1,
20 HLIM-2, and HLIM-3 having chemical homology to the LIM proteins above and as shown in amino acid sequences SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5, respectively.

One aspect of the invention features isolated and substantially purified polynucleotides that encode HLIM proteins HLIM-1, HLIM-2, and HLIM-3. In a particular aspect, the polynucleotides are the nucleotide sequences of SEQ ID NO:2, SEQ ID NO:4, or
25 SEQ ID NO:6, respectively.

The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.

30 The invention additionally features nucleic acid sequences encoding polypeptides, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode HLIM. The present invention also features antibodies which bind specifically to HLIM, and pharmaceutical compositions comprising substantially purified HLIM. The invention also

5 features the use of agonists and antagonists of HLIM.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A and 1B show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of HLIM-1. The alignment was produced using MacDNASIS PRO™ software (Hitachi Software Engineering Co., Ltd., San Bruno, CA).

10 Figures 2A, 2B, 2C and 2D show the amino acid sequence (SEQ ID NO:3) and nucleic acid sequence (SEQ ID NO:4) of HLIM-2.

Figures 3A, 3B, 3C and 3D show the amino acid sequence (SEQ ID NO:5) and nucleic acid sequence (SEQ ID NO:6) of HLIM-3.

Figure 4 shows the amino acid sequence alignments among HLIM-1 (SEQ ID NO:1),
15 human CRP (GI 118161; SEQ ID NO:7) and MLP (GI 1234841; SEQ ID NO:8), and rat smLIM (GI 1314351; SEQ ID NO:9). The alignment was produced using the multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

Figures 5A and 5B shows the amino acid sequence alignments among HLIM-2 (SEQ ID NO:3), rat CLP36 (GI 1020151; SEQ ID NO:10) and rat RIL (GI 887580; SEQ ID
20 NO:11).

Figures 6A and 6B shows the amino acid sequence alignments among HLIM-3 (SEQ ID NO:5), rat proteins CLP36 (GI 1020151; SEQ ID NO:10) and rat RIL (GI 887580; SEQ ID NO:11).

Figure 7 shows the hydrophobicity plot (MacDNASIS PRO software) for HLIM-1,
25 SEQ ID NO:1; the positive X axis reflects amino acid position, and the negative Y axis, hydrophobicity.

Figure 8 shows the hydrophobicity plot for rat smLIM, SEQ ID NO:9.

Figure 9 shows the hydrophobicity plot for HLIM-2, SEQ ID NO:3.

Figure 10 shows the hydrophobicity plot for HLIM-3, SEQ ID NO:5.

30 Figure 11 shows the hydrophobicity plot for rat CLP36, SEQ ID NO:10.

Figure 12 shows the northern analysis for SEQ ID NO:2. The northern analysis was produced electronically using LIFESEQ™ database (Incyte Pharmaceuticals, Inc., Palo Alto, CA).

Figures 13A, 13B, 13C, 13D, 13E, 13F, 13G and 13H shows the northern analysis for

5 SEQ ID NO:6.

MODES FOR CARRYING OUT THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, "amino acid sequence" as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence and fragments or portions thereof, of a naturally occurring or synthetic molecule.

Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a

5 naturally occurring protein molecule. "amino acid sequence" and like terms, such as "polypeptide" or "protein" are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Peptide nucleic acid", as used herein, refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been
10 added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary strand of nucleic acid (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

HLIM, as used herein, refers to the amino acid sequences of substantially purified HLIM obtained from any species, particularly mammalian, including bovine, ovine, porcine,
15 murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

"Consensus", as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, or which has been extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or which has been
20 assembled from the overlapping sequences of more than one Incyte clone using the GELVIEW™ Fragment Assembly system (GCG, Madison, WI), or which has been both extended and assembled.

A "variant" of HLIM, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a
25 substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity
30 may be found using computer programs well known in the art, for example, DNASTAR software.

A "deletion", as used herein, refers to a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent.

An "insertion" or "addition", as used herein, refers to a change in an amino acid or

5 nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the naturally occurring molecule.

A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

The term "biologically active", as used herein, refers to a protein having structural,
10 regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic HLIM, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "agonist", as used herein, refers to a molecule which, when bound to HLIM,
15 causes a change in HLIM which modulates the activity of HLIM. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to HLIM.

The terms "antagonist" or "inhibitor", as used herein, refer to a molecule which, when bound to HLIM, blocks the biological or immunological activity of HLIM. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecules which
20 bind to HLIM.

The term "modulate", as used herein, refers to a change or an alteration in the biological activity of HLIM. Modulation may be an increase or a decrease in protein activity, a change in binding characteristics, or any other change in the biological, functional or immunological properties of HLIM.

25 The term "mimetic", as used herein, refers to a molecule, the structure of which is developed from knowledge of the structure of HLIM or portions thereof and, as such, is able to effect some or all of the actions of LIM protein-like molecules.

The term "derivative", as used herein, refers to the chemical modification of a nucleic acid encoding HLIM or the encoded HLIM. Illustrative of such modifications would be
30 replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a polypeptide which retains essential biological characteristics of the natural molecule.

The term "substantially purified", as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at

- 5 least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

“Amplification” as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR
10 Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

The term “hybridization”, as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term “hybridization complex”, as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen binds between
15 complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid
20 support (e.g., membranes, filters, chips, pins or glass slides to which cells have been fixed for in situ hybridization).

The terms “complementary” or “complementarity”, as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, for the sequence “A-G-T” binds to the complementary sequence “T-C-
25 A”. Complementarity between two single-stranded molecules may be “partial”, in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon
30 binding between nucleic acids strands.

The term “homology”, as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence is one that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid; it is referred to using the functional term “substantially homologous.”

5 The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence or probe to the target sequence under conditions of low
10 stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding,
15 the probe will not hybridize to the second non-complementary target sequence.

As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other
20 components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about $T_m - 5^\circ\text{C}$ (5°C below the melting temperature (T_m) of the probe) to
25 about 20°C to 25°C below T_m . As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

The term "antisense", as used herein, refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in
30 reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a complementary strand. Once introduced into a cell, this transcribed strand combines with natural sequences produced by the cell to form duplexes. These duplexes then block either

5 the further transcription or translation. In this manner, mutant phenotypes may be generated. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

The term "portion", as used herein, with regard to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four
10 amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:1" encompasses the full-length human HLIM-1 and fragments thereof.

"Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using
15 various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, viral infection, electroporation, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of
20 replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

The term "antigenic determinant", as used herein, refers to that portion of a molecule that makes contact with a particular antibody (i.e., an epitope). When a protein or fragment
25 of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

30 The terms "specific binding" or "specifically binding", as used herein, in reference to the interaction of an antibody and a protein or peptide, mean that the interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) on the protein; in other words, the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the

- 5 presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding HLIM or fragments thereof may comprise a cell, chromosomes isolated from a cell (e.g., a spread of metaphase chromosomes), genomic
10 DNA (in solution or bound to a solid support such as for Southern analysis), RNA (in solution or bound to a solid support such as for northern analysis), cDNA (in solution or bound to a solid support), an extract from cells or a tissue, and the like.

The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2, SEQ ID
15 NO:4, or SEQ ID NO:6 by northern analysis is indicative of the presence of mRNA encoding HLIM in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

"Alterations" in the polynucleotide of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, as used herein, comprise any alteration in the sequence of polynucleotides encoding
20 HLIM including deletions, insertions, and point mutations that may be detected using hybridization assays. Included within this definition is the detection of alterations to the genomic DNA sequence which encodes HLIM (e.g., by alterations in the pattern of restriction fragment length polymorphisms capable of hybridizing to SEQ ID NO:2, SEQ ID NO:4, or
SEQ ID NO:6), the inability of a selected fragment of SEQ ID NO:2, SEQ ID NO:4, or SEQ
25 ID NO:6 to hybridize to a sample of genomic DNA (e.g., using allele-specific oligonucleotide probes), and improper or unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HLIM (e.g., using fluorescent in situ hybridization (FISH) to metaphase chromosomes spreads).

As used herein, the term "antibody" refers to intact molecules as well as fragments
30 thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind HLIM polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal can be derived from translated RNA or synthesized chemically, and can be conjugated to a carrier protein, if desired. Commonly used carriers

5 that are chemically coupled to peptides include bovine serum albumin and thyroglobulin.
The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

10 THE INVENTION

The invention is based on the discovery of three novel human LIM proteins (HLIM-1, HLIM-2, and HLIM-3, collectively referred to as HLIM), the polynucleotides encoding HLIM, and the use of these compositions for the diagnosis, prevention, or treatment of cancer, arteriosclerosis, or other diseases or conditions relating to abnormal regulation of cell
15 growth.

Nucleic acids encoding the human HLIM-1 of the present invention were first identified in Incyte Clone 305288 from an adult heart tissue cDNA library (HEARNOT01) through a computer-generated search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended
20 nucleic acid sequences (cDNA library from which derived): Incyte Clones 305288, 305719, 305804, 307231 (HEARNOT01); 532714 (BRAINOT03); 963636 (BRSTTUT03); 1004370 (BRSTNOT03); 1266381 (BRAINOT09); and 1436648 (PANCNOT08).

Nucleic acids encoding the human HLIM-2 of the present invention were first identified in Incyte Clone 267324 from an hNT2 cell line cDNA library (HNT2NOT01)
25 through a computer-generated search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:4, was derived from the following overlapping and/or extended nucleic acid sequences (cDNA library from which derived): Incyte Clones 970132 (MUSCNOT02); 778312 (COLNNOT05); 1291737 (PGANNOT03); 1504324 (BRAITUT07); 922412 (RATRNOT02); 1349314 (LATRTUT02); and 267324
30 (HNT2NOT01).

Nucleic acids encoding the human HLIM-3 of the present invention were first identified in Incyte Clone 1429619, from an ileum tissue cDNA library (SINTBST01) through a computer-generated search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:6, was derived from the following overlapping and/or extended

5 nucleic acid sequences (cDNA library from which derived): Incyte Clones 1429619 (SINTBST01); 425837 (BLADNOT01); 1823189 (GBLATUT01); 922744 (RATRNOT02); 352494 (LVENNOT01); and 766348 (LUNGNOT04).

In one embodiment, the invention encompasses the novel human LIM protein HLIM-1, a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figures 1A and 1B. HLIM-1 is 193 amino acids in length and contains a potential nuclear localization motif comprising K₆₄K₆₅Y₆₆G₆₇P₆₈K₆₉. In addition, HLIM-1 contains a potential protein kinase C phosphorylation site at T₁₅₉ and a potential tyrosine kinase phosphorylation site at Y₁₂₁. As shown in Figure 4, HLIM-1 has chemical and structural homology with human CRP (GI 118161; SEQ ID NO:7) human MLP (GI 1234841; SEQ ID NO:8), and rat smLIM (GI 1314351; SEQ ID NO:9). In particular, HLIM-1 shares 81%, 67%, and 97% identity with human CRP, human MLP and rat smLIM, respectively. As illustrated by Figures 7 and 8, HLIM and rat smLIM have similar hydrophobicity plots. HLIM-1 contains two LIM domains spanning positions C₁₀ to C₆₁ and C₁₁₉ to C₁₇₀. The amino acid motifs which define these domains, consisting of C-X₂-C-X₍₁₇₋₁₉₎-H-X₂-C-X₂-C-X₂-C-X₍₁₆₋₂₀₎-C-X₂-C, are precisely conserved in CRP, MLP and smLIM. From the northern analysis (Figure 12), HLIM-1 is abundantly expressed in heart and bladder tissue CDNA libraries, which suggests a specific role in smooth muscle cell and possibly cardiac muscle cell function. In addition, HLIM-1 is found in several fetal tissue libraries, which suggests a developmental role for this molecule. Expression of HLIM-1 appears to decrease in tumor associated tissues; for instance, HLIM-1 expression is decreased in 20-fold in heart myoma tumor tissue as compared to normal heart tissue.

In another embodiment, the invention encompasses the novel human LIM protein HLIM-2, a polypeptide comprising the amino acid sequence of SEQ ID NO:3, as shown in Figures 2A, 2B, 2C and 2D. HLIM-2 is 329 amino acids in length. As shown in Figure 5, HLIM-2 has chemical and structural homology with rat CLP36 (GI 1020151; SEQ ID NO:10) and rat RIL (GI 887580; SEQ ID NO:11). In particular, HLIM-2 and CLP36 share 88% identity, whereas HLIM-2 and RIL share 44 % identity. As illustrated by Figures 9 and 11, HLIM-2 and CLP36 have rather similar hydrophobicity plots. HLIM-2 contains a single LIM domain, defined by amino acids C₂₆₀, C₂₆₃, H₂₈₀, C₂₈₃, C₂₈₆, C₂₈₉, C₃₀₇ and H₃₁₀, which is

5 precisely conserved in CLP36 and RIL. Northern analysis (not shown) reveals the expression of this sequence in 222 cDNA libraries prepared from a wide variety of tissues, with highest abundance in breast, ovary, uterus, lung, heart, skeletal muscle, and synovium. The expression of sequences encoding HLIM-2 appears to be diminished in tumor-associated tissues. Only one of the 40 libraries which express the highest abundance of HLIM-2 are
10 tumor-associated. In particular, tumor-associated tissue from breast and lung contain significantly less HLIM-2 mRNA than normal breast and lung tissue.

In an additional embodiment, the invention encompasses the novel human LIM protein HLIM-3, a polypeptide comprising the amino acid sequence of SEQ ID NO:5, as shown in Figures 3A, 3B and 3C. HLIM-3 is 316 amino acids in length. As shown in Figure
15 6, HLIM-3 has chemical and structural homology with rat CLP36 (GI 1020151; SEQ ID NO:10) and rat RIL (GI 887580; SEQ ID NO:11). In particular, HLIM-3 and CLP36 share 53% identity, whereas HLIM-3 and RIL share 45% identity. As illustrated by Figures 10 and 11, HLIM-3 and CLP36 have rather similar hydrophobicity plots. The single LIM domain of HLIM-3, defined by amino acids C₂₄₆, C₂₄₉, H₂₆₆, C₂₆₉, C₂₇₂, C₂₇₅, C₂₉₃, and H₂₉₆, is precisely
20 conserved in CLP36 and RIL. Northern analysis (Figure 13) shows the expression of this sequence is most abundant in skeletal muscle. HLIM-3 encoding sequences are also expressed in cDNA libraries related to smooth and cardiac muscle including heart, ovary, stomach, bladder, prostate, breast, and colon. The expression of sequences encoding HLIM-3 appears to be diminished in tumor-associated tissues; of the 43 libraries which express
25 HLIM-3, only 5 are tumor-associated.

The invention also encompasses HLIM variants. A preferred HLIM variant is one having at least 80%, and more preferably 90%, amino acid sequence similarity to the HLIM amino acid sequence (SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5). A most preferred HLIM variant is one having at least 95% amino acid sequence similarity to SEQ ID NO:1,
30 SEQ ID NO:3, or SEQ ID NO:5.

The invention also encompasses polynucleotides which encode HLIM. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of HLIM can be used to generate recombinant molecules which express HLIM. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid of SEQ ID NO:2, SEQ

5 ID NO:4, or SEQ ID NO:6 as shown in Figures 1A, 1B, 2A, 2B, 2C, 2D, 3A, 3, 3C and 3D.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding HLIM, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide
10 sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring HLIM, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode HLIM and its variants are preferably
15 capable of hybridizing to the nucleotide sequence of the naturally occurring HLIM under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HLIM or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with
20 which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HLIM and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of a DNA sequence, or portions thereof,
25 which encode HLIM and its derivatives, entirely by synthetic chemistry. After production, the synthetic gene may be inserted into any of the many available DNA vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding HLIM or any portion thereof.

30 Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, under various conditions of stringency.

Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex or probe, as taught in Kimmel, A.R. (1987; Methods Enzymol. Vol. 152),

5 and may be used at a defined stringency.

Altered nucleic acid sequences encoding HLIM which are encompassed by the invention include deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent HLIM. The encoded protein may also contain deletions, insertions, or substitutions of amino acid residues which
10 produce a silent change and result in a functionally equivalent HLIM. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of HLIM is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine
15 and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.

Also included within the scope of the present invention are alleles of the gene encoding HLIM. As used herein, an "allele" or "allelic sequence" is an alternative form of
20 the gene which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in
25 combination with the others, one or more times in a given sequence.

Methods for DNA sequencing which are well known and generally available in the art may be used to practice any embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham,
30 Chicago, IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI 377 DNA sequencers (Perkin Elmer).

- 5 The polynucleotide sequence encoding HLIM may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In
- 10 particular, genomic DNA is first amplified in the presence of primer to linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.
- 15 Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers may be designed using OLIGO® 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN); or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about
- 20 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.
- Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial
- 25 chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before performing PCR.
- Another method which may be used to retrieve unknown sequences is that of Parker,
- 30 J.D. et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk in genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and may be is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been

5 size-selected to include larger cDNAs. Also, random-primed libraries are preferable in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into the 5' and 3' non-transcribed regulatory regions.

10 Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled devise camera. Output/light
15 intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence Navigator™, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

20 In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HLIM, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of HLIM in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and
25 these sequences may be used to clone and express HLIM.

As will be understood by those of skill in the art, it may be advantageous to produce HLIM-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having
30 desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter the HLIM coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or

5 expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequence. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, to change codon preference, to produce splice variants, or other mutations, and so forth.

10 In another embodiment of the invention, a natural, modified, or recombinant polynucleotide encoding HLIM may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of HLIM activity, it may be useful to encode a chimeric HLIM protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between
15 a HLIM encoding sequence and the heterologous protein sequence, so that HLIM may be cleaved and purified away from the heterologous moiety.

In another embodiment, the coding sequence of HLIM may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser.
20 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the HLIM amino acid sequence, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

25 The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of HLIM,
30 or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active HLIM, the nucleotide sequence encoding HLIM or functional equivalents, may be inserted into an appropriate expression vector, i.e., a

5 vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing a HLIM coding sequence and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques,
10 synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

A variety of expression vector/host systems may be utilized to contain and express a
15 HLIM coding sequence. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or
20 with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of
25 suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and ptrp-lac hybrids, and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or
30 enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding HLIM, vectors based on SV40 or EBV may be used

5 with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for HLIM. For example, when large quantities of HLIM are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional
10 E. coli cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding HLIM may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to
15 express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released
20 from the GST moiety at will.

In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

In cases where plant expression vectors are used, the expression of a sequence
25 encoding HLIM may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al.
30 (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.

5 An insect system may also be used to express HLIM. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequence encoding HLIM may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of HLIM
10 will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which HLIM may be expressed (Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227).

 In mammalian host cells, a number of viral-based expression systems may be utilized.
15 In cases where an adenovirus is used as an expression vector, a sequence encoding HLIM may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing HLIM in infected host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In
20 addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

 Specific initiation signals may also be used to achieve more efficient translation of a sequence encoding HLIM. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding HLIM, its initiation codon, and upstream
25 sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational
30 elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

 In addition, a host cell strain may be chosen for its ability to modulate the expression

5 of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and WI38,
10 which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express HLIM may be transformed using
15 expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which
20 successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980)
25 Cell 22:817-23) genes which can be employed in tk⁻ or apt⁻ cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer
30 resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins,

5 β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of
10 interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding HLIM is inserted within a marker gene sequence, recombinant cells containing sequences encoding HLIM can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HLIM under the control of a single promoter. Expression of the marker gene in response to
15 induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the coding sequence for HLIM and express HLIM may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip
20 based technologies for the detection and/or quantification of the nucleic acid or protein.

The presence of the polynucleotide sequence encoding HLIM can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or portions or fragments of polynucleotides encoding HLIM. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the HLIM-encoding sequence to
25 detect transformants containing DNA or RNA encoding HLIM. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplimer.

A variety of protocols for detecting and measuring the expression of HLIM, using
30 either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HLIM is preferred, but a competitive binding assay may be employed. These and other assays are

5 described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983) J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing
10 labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HLIM include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequence encoding HLIM, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by
15 addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn (Kalamazoo, MI); Promega (Madison, WI); and U.S. Biochemical Corp. (Cleveland, OH). Suitable reporter molecules or labels, which may be used, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as
20 substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with a nucleotide sequence encoding HLIM may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in
25 the art, expression vectors containing polynucleotides which encode HLIM may be designed to contain signal sequences which direct secretion of HLIM through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding HLIM to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not
30 limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA)

5 between the purification domain and HLIM may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing HLIM and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography) as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3: 263-281) while
10 the enterokinase cleavage site provides a means for purifying HLIM from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

In addition to recombinant production, fragments of HLIM may be produced by direct peptide synthesis using solid-phase techniques (cf Stewart et al. (1969) Solid-Phase Peptide
15 Synthesis, W.H. Freeman Co., San Francisco, CA; Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of HLIM may be chemically synthesized separately and combined using chemical methods to produce the full length
20 molecule.

THERAPEUTICS

In another embodiment of the invention, HLIM or fragments thereof may be used for therapeutic purposes.

The rationale for the therapeutic use of the HLIM sequences disclosed herein are
25 based in part on the chemical and structural homology among HLIM-1, human MLP and rat smLIM, and among HLIM-2, HLIM-3, rat CLP36 and rat RIL. Furthermore, the expression patterns of HLIM suggest a role in promoting or maintaining normal tissue growth and differentiation. HLIM-1 and HLIM-3 are expressed primarily in muscle tissues, whereas HLIM-2 is expressed in a wide variety of tissues.

30 Since expression of HLIM appears to be negatively correlated with cancer (Figures 12 and 13, and as discussed above), vectors containing the nucleic acid sequence encoding HLIM may be used to promote differentiation and to restore tumor cells to a normal phenotype. These vectors could be delivered into tumors or cancerous cells using technologies well known in the art or as an adjunct to biopsy of the cancer. Control of HLIM

5 activity as a novel approach to cancer treatment may be especially useful in combination therapy with other, conventional chemotherapeutic agents. Such combinations of therapeutic agents having different cellular mechanisms of action often have synergistic effects allowing the use of lower effective doses of each agent and lessening side effects.

10 In another embodiment, vectors expressing antisense, and antagonists or inhibitors of the protein may be used to induce proliferation or regeneration of cells, tissues and organs which are not readily regenerated. Regeneration and development of nerve, pancreatic, epithelial, etc. tissue will involve supplying various molecules including HLIM antagonists in drug regimes that allow cell division to occur. Small amounts of new functional tissue have the capacity to greatly improve the quality of life for victims of accidents or degenerative
15 diseases. Furthermore, HLIM antagonists may be useful in stimulating skin production in vitro or ex vivo for use in skin grafts.

In another embodiment, antagonists which block or modulate the effect of HLIM may be used in those situations where such inhibition is therapeutically desirable. Such antagonists or inhibitors may be produced using methods which are generally known in the
20 art, and include particularly the use of purified HLIM to produce antibodies or to screen libraries of pharmaceutical agents for those which specifically bind HLIM. For example, in one aspect, antibodies which are specific for HLIM may be used directly as an antagonist, or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express HLIM.

25 The antibodies may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

30 For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with HLIM or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active

5 substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the peptides, fragments, or oligopeptides used to induce antibodies to HLIM have an amino acid sequence consisting of at least five amino acids, and more
10 preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HLIM amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

15 Monoclonal antibodies to HLIM may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Koehler et al. (1975) Nature 256:495-497; Kosbor et al. (1983) Immunol. Today 4:72; Cote et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; Cole et al. (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss Inc., New York, NY, pp.
20 77-96).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al. (1984)
25 Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger et al. (1984) Nature 312:604-608; Takeda et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce HLIM-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial
30 immunoglobulin libraries (Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:11120-3).

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

5 Antibody fragments which contain specific binding sites for HLIM may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy
10 identification of monoclonal Fab fragments with the desired specificity (Huse et al. (1989) Science 256:1275-1281).

 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well
15 known in the art. Such immunoassays typically involve the measurement of complex formation between HLIM and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HLIM epitopes is preferred, but a competitive binding assay may also be employed (Maddox, supra).

 In another embodiment of the invention, the polynucleotides encoding HLIM, or any
20 fragment thereof, or antisense sequences, may be used for therapeutic purposes. In one aspect, antisense to the polynucleotide encoding HLIM may be used in situations in which it would be desirable to block the synthesis of the protein. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HLIM. Thus, antisense sequences may be used to modulate HLIM activity, or to achieve regulation of gene
25 function. Such technology is now well known in the art, and sense or antisense oligomers or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding HLIM.

 Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the
30 targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense polynucleotides of the gene encoding HLIM. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).

 Genes encoding HLIM can be turned off by transforming a cell or tissue with

5 expression vectors which express high levels of a polynucleotide or fragment thereof which encodes HLIM. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even
10 longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA, or PNA, to the control regions of the gene encoding HLIM, i.e., the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly,
15 inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches,
20 Futura Publishing Co., Mt. Kisco, NY). The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by
25 endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding HLIM.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the
30 following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease

5 protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding HLIM. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any suitable subject including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

30 An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HLIM, antibodies to HLIM, mimetics, agonists, antagonists, or inhibitors of HLIM. The compositions may be administered alone or in combination with at least one other agent,

5 such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by
10 any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which
15 facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using
20 pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of
25 active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium
30 carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated

5 sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

10 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

15 Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active
20 compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

25 For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

30 The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

 The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized

5 powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of HLIM, such labeling would include amount, frequency, and method of administration.

10 Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either
15 in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example
20 HLIM or fragments thereof, antibodies of HLIM, agonists, antagonists or inhibitors of HLIM, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the
25 therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this
30 range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be

5 taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

10 Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be
15 specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind HLIM may be used for the diagnosis of conditions or diseases characterized by expression of HLIM, or in assays to monitor patients being treated with HLIM, agonists, antagonists or inhibitors. The antibodies
20 useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for HLIM include methods which utilize the antibody and a label to detect HLIM in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules
25 which are known in the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring HLIM are known in the art and provide a basis for diagnosing altered or abnormal levels of HLIM expression. Normal or standard values for HLIM expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with
30 antibody to HLIM under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric, means. Quantities of HLIM expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

5 In another embodiment of the invention, the polynucleotides encoding HLIM may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of HLIM may be correlated with disease. The diagnostic assay may be
10 used to distinguish between absence, presence, and excess expression of HLIM, and to monitor regulation of HLIM levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding HLIM or closely related molecules, may be used to identify nucleic acid sequences which encode HLIM. The
15 specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding HLIM, alleles, or related sequences.

20 Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the HLIM encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring
25 HLIM.

Means for producing specific hybridization probes for DNAs encoding HLIM include the cloning of nucleic acid sequences encoding HLIM or HLIM derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the
30 appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as ³²P or ³⁵S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding HLIM may be used for the diagnosis of

5 conditions or diseases which are associated with expression of HLIM. Examples of such conditions or diseases include cancers of the heart, breast, colon, and prostate, and diseases associated with proliferation of smooth muscle cells such as arteriosclerosis. The polynucleotide sequences encoding HLIM may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dip stick, pin, ELISA
10 or chip assays utilizing fluids or tissues from patient biopsies to detect altered HLIM expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding HLIM may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequence encoding HLIM may be labeled by standard methods, and
15 added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequence has hybridized with nucleotide sequences in the sample, and the
20 presence of altered levels of nucleotide sequences encoding HLIM in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of
25 HLIM, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes HLIM, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount
30 of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays

5 may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

10 With respect to cancer, the presence of a relatively low amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

15 Additional diagnostic uses for oligonucleotides encoding HLIM may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'→3') and another with antisense (3'←5'), employed under optimized conditions for identification of a specific gene or condition. The same two
20 oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HLIM include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and
25 standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

30 In another embodiment of the invention, the nucleic acid sequence which encodes HLIM may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include FISH, FACS, or artificial chromosome constructions, such as yeast

5 artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) *Blood Rev.* 7:127-134, and Trask, B.J. (1991) *Trends Genet.* 7:149-154.

FISH (as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical
10 chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of *Science* (265:1981f). Correlation between the location of the gene encoding HLIM on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect
15 differences in gene sequences between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a
20 particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988)
25 *Nature* 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, HLIM, its catalytic or immunogenic
30 fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between HLIM and the agent being tested, may be measured.

5 Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to HLIM large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with HLIM, or fragments
10 thereof, and washed. Bound HLIM is then detected by methods well known in the art. Purified HLIM can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which
15 neutralizing antibodies capable of binding HLIM specifically compete with a test compound for binding HLIM. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HLIM.

In additional embodiments, the nucleotide sequences which encode HLIM may be used in any molecular biology techniques that have yet to be developed, provided the new
20 techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

INDUSTRIAL APPLICABILITY

25 I cDNA Library Construction HEARNOT01

The HEARNOT01 library was constructed from heart tissue obtained from a 56 year-old Caucasian male (Lot No. HAL194, International Institute for the Advancement of Medicine (IIAM), Exton, PA).

30 The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron PT-3000 (Brinkmann Instruments, Westbury, NJ) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using an Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Instruments) for 18 hours at 25,000 rpm at ambient temperature. The RNA was extracted with acid phenol pH 4.0, precipitated

5 using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNase-free water, and DNase treated at 37°C. The RNA extraction was repeated with acid phenol pH 4.0 and precipitated with sodium acetate and ethanol as before. The mRNA was then isolated using the Qiagen Oligotex kit (Qiagen, Inc., Chatsworth, CA) and used to construct the cDNA library.

10 First strand cDNA synthesis was accomplished using an oligo d(T) primer/linker which also contained an XhoI restriction site. Second strand synthesis was performed using a combination of DNA polymerase I, E. coli ligase and RNase H, followed by the addition of an EcoRI adaptor to the blunt ended cDNA. The EcoRI adapted, double-stranded cDNA was then digested with XhoI restriction enzyme and fractionated to obtain sequences which
15 exceeded 800 bp in size. The cDNAs were inserted into the LambdaZap® vector system (Stratagene); then the vector which contained the pBluescript phagemid (Stratagene) was transformed into E. coli host cells strain XL1-BlueMRF™ (Stratagene).

The phagemid forms of individual cDNA clones were obtained by the in vivo excision process. Enzymes from both pBluescript and a cotransformed f1 helper phage nicked the
20 DNA, initiated new DNA synthesis, and created the smaller, single-stranded circular phagemid molecules which contained the cDNA insert. The phagemid DNA was released, purified, and used to reinfect fresh host cells (SOLR, Stratagene). Presence of the phagemid which contained the gene for β -lactamase allowed transformed bacteria to grow on medium containing ampicillin.

25 HNT2NOT01

The hNT2 cell line exhibits characteristics of a committed neuronal precursor cell which is still at an early stage of development. The HNT2NOT01 cDNA library prepared from this untreated cell line was obtained from Stratagene (Cat. No. 937230). The cDNA library was constructed by essentially the following procedure. cDNAs were primed using
30 oligo d(T) and size fractionated to isolate fragments of 500 bp and larger. Synthetic adapter oligonucleotides were ligated onto the cDNA molecules enabling them to be inserted into the Uni-ZAP™ vector system (Stratagene). The quality of the cDNA library was screened using DNA probes, and then, the pBluescript phagemid (Stratagene) was excised. Subsequently, the custom-constructed library phage particles were infected into E. coli host strain XL1-

5 Blue® (Stratagene).

SINTBST01

The SINTBST01 cDNA library was constructed from Crohn's disease affected small intestine tissue obtained from an 18-year-old Caucasian female (specimen #0256A; Mayo Clinic, Rochester, MN). This tissue was associated with cDNA library COLNNOT19 which
10 was microscopically normal colon tissue from the same patient. The patient presented with abdominal pain and symptoms of enteritis; the following tissue was excised during anastomosis: 16 cm segment of ileum with 5 cm segment of cecum, and 5.5 x 0.4 cm of appendix. Crohn's disease was identified involving 15 cm of the small bowel. The cecum and appendix were unremarkable, and the margins were uninvolved. The patient was treated
15 with Priloxec® (omeprazole for abdominal pain; Astra/Merck Group of Merck & Co., Wayne, PA); Pentasa® (mesalamine for colitis; Marion Merrell Dow, Kansas City, MO); and Amoxicillian (penicillin). The patient history included abnormal blood chemistry and osteoporosis. Family history included cerebrovascular disease in mother and grandparent and cardiovascular disease in a grandparent.

20 Ileum mRNA was extracted from the tissue and purified essentially as described for the HEARNOT01 library. The mRNA was handled according to the recommended protocols in the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat. No. 18248-013, Gibco/BRL).

The commercial plasmid pSPORT 1 (Gibco/BRL) was digested with EcoR I
25 restriction enzyme (New England Biolabs, Beverley, MA). The overhanging ends of the plasmid were filled in using Klenow enzyme (New England Biolabs) and 2'-deoxynucleotide 5'-triphosphates (dNTPs). The plasmid was self-ligated and transformed into the bacterial host, *E. coli* strain JM 109. An intermediate plasmid produced by the bacteria failed to digest with EcoR I confirming the desired loss of the EcoR I restriction site.

30 This intermediate plasmid (pSPORT 1-ΔRI) was then digested with Hind III restriction enzyme (New England Biolabs) and the overhang was filled in with Klenow and dNTPs. A 10-mer linker of sequence 5'...CGGAATTCCG...3' was phosphorylated and ligated onto the blunt ends. The product of the ligation reaction was digested with EcoR I and self-ligated. Following transformation into JM109 host cells, plasmids were isolated and screened

5 for the digestibility with EcoR I but not with Hind III. A single colony which met this criteria was designated pINCY I. The plasmid produced by this colony was sequenced and found to contain several copies of the 10-mer linker. These extra linkers did not present a problem as they were eliminated when the vector was prepared for cloning.

The plasmid was tested for its ability to incorporate cDNAs from a library prepared
10 using Not I and EcoR I restriction enzymes. Several clones were sequenced and a single clone containing an insert of approximately 0.8 kb was selected to prepare a large quantity of the plasmid for library production. After digestion with Not I and EcoR I, the plasmid and the cDNA insert were isolated on an agarose gel and the vector was purified on a QIAQuick (Qiagen, Inc.) column for use in library construction.

15 cDNAs were fractionated on a Sepharose CL4B column (Cat. No. 275105-01, Pharmacia Upjohn), and those cDNAs exceeding 400 bp were ligated into pSport I. The plasmid pSport I was subsequently transformed into DH5a™ competent cells (Cat. No. 18258-012, Gibco/BRL).

II Isolation and Sequencing of cDNA Clones

20 Plasmid or phagemid DNA was released from cells and purified using the Miniprep Kit (Cat. No. 77468; Advanced Genetic Technologies Corporation, Gaithersburg MD). This kit consists of a 96 well block with reagents for 960 purifications. The recommended protocol was employed except for the following changes: 1) the 96 wells were each filled with only 1 ml of sterile Terrific Broth (Cat. No. 22711, LIFE TECHNOLOGIES™, Gaithersburg MD) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) the bacteria were
25 cultured for 24 hours after the wells were inoculated and then lysed with 60 µl of lysis buffer; 3) a centrifugation step employing the Beckman GS-6R at 2900 rpm for 5 min was performed before the contents of the block were added to the primary filter plate; and 4) the optional step of adding isopropanol to TRIS buffer was not routinely performed. After the last step in
30 the protocol, samples were transferred to a Beckman 96-well block for storage.

Alternative methods of purifying plasmid DNA include the use of MAGIC MINIPREPS™ DNA Purification System (Cat. No. A7100, Promega) or QIAwell™-8 Plasmid, QIAwell PLUS DNA and QIAwell ULTRA DNA Purification Systems (Qiagen, Inc.).

5 The cDNAs were sequenced by the method of Sanger F. and A.R. Coulson (1975; J. Mol. Biol. 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno NV) in combination with four Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown MA) and Applied Biosystems 377 or 373 DNA Sequencing Systems (Perkin Elmer) and reading frame was determined.

10 **III Homology Searching of cDNA Clones and Their Deduced Proteins**

Each cDNA was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT™ 670 sequence analysis system. In this algorithm, Pattern Specification Language (TRW Inc, Los Angeles, CA) was used to determine regions of homology. The three parameters that determine how
15 the sequence comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches.

20 Smith-Waterman alignments were used to display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT- 670 sequence analysis system using the methods similar to those used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an
25 initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches.

BLAST, which stands for Basic Local Alignment Search Tool (Altschul, S.F. (1993) J. Mol. Evol. 36:290-300; Altschul et al. (1990) J. Mol. Biol. 215:403-410), was used to search for local sequence alignments. BLAST produces alignments of both nucleotide and
30 amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. BLAST is useful for matches which do not contain gaps. The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose

5 alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user. The BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting
10 database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.

IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript
15 of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., supra).

Analogous computer techniques using BLAST (Altschul, S.F. 1993 and 1990, supra) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than
20 multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

25

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although
30 lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding HLIM occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences

5 examined in the cDNA library.

V Extension of HLIM-Encoding Polynucleotides to Full Length or to Recover Regulatory Sequences

Full length HLIM-encoding nucleic acid sequence (SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6) is used to design oligonucleotide primers for extending a partial nucleotide
 10 sequence to full length or for obtaining 5' or 3', intron or other control sequences from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers are used to facilitate the extension of the known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers
 15 are designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations is avoided.

20 The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region.

By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly
 25 mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

30	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec
	Step 5	65° C for 1 min
35	Step 6	68° C for 7 min
	Step 7	Repeat step 4-6 for 15 additional cycles

- | | | |
|----|---------|--------------------------------|
| 5 | Step 8 | 94° C for 15 sec |
| | Step 9 | 65° C for 1 min |
| | Step 10 | 68° C for 7:15 min |
| | Step 11 | Repeat step 8-10 for 12 cycles |
| | Step 12 | 72° C for 8 min |
| 10 | Step 13 | 4° C (and holding) |

A 5-10 μ l aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products are selected and removed from the gel. Further purification involves using a commercial gel extraction method such as QIAQUICK (Qiagen Inc.). After recovery of the DNA, Klenow enzyme is used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning.

After ethanol precipitation, the products are redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase are added, and the mixture is incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) are transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook et al., supra). After incubation for one hour at 37° C, the whole transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook et al., supra) containing 2x Carb. The following day, several colonies are randomly picked from each plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture is transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample is transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction are added to each well. Amplification is performed using the following conditions:

- | | | |
|----|--------|------------------|
| 35 | Step 1 | 94° C for 60 sec |
| | Step 2 | 94° C for 20 sec |
| | Step 3 | 55° C for 30 sec |

- 5 Step 4 72° C for 90 sec
 Step 5 Repeat steps 2-4 for an additional 29 cycles
 Step 6 72° C for 180 sec
 Step 7 4° C (and holding)

10 Aliquots of the PCR reactions are run on agarose gels together with molecular weight markers. The sizes of the PCR products are compared to the original partial cDNAs, and appropriate clones are selected, ligated into plasmid, and sequenced.

VI Labeling and Use of Hybridization Probes

Hybridization probes derived from SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6
 15 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 mCi of [γ -³²P] adenosine triphosphate (Amersham) and T4
 20 polynucleotide kinase (DuPont NEN®, Boston, MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A portion containing 10⁷ counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II;
 25 DuPont NEN®).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x
 30 saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester, NY) is exposed to the blots in a Phosphorimager cassette (Molecular Dynamics, Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

VII Antisense Molecules

Antisense molecules to the HLIM-encoding sequence, or any part thereof, is used to
 35 inhibit in vivo or in vitro expression of naturally occurring HLIM. Although use of antisense

5 oligonucleotides, comprising about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide based on the coding sequences of HLIM, as shown in Figures 1A, 1B, 2A, 2B, 2C, 2D, 3A, 3B, 3C and 3D, is used to inhibit expression of naturally occurring HLIM. The complementary oligonucleotide is designed from the most unique 5' sequence as shown in Figures 1A, 1B, 2A, 2B, 2C, 2D,
10 3A, 3B, 3C and 3D and used either to inhibit transcription by preventing promoter binding to the upstream nontranslated sequence or translation of an HLIM-encoding transcript by preventing the ribosome from binding. Using an appropriate portion of the signal and 5' sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the
15 signal or 5' coding sequence of the polypeptide as shown in Figures 1A, 1B, 2A, 2B, 2C, 2D, 3A, 3B, 3C and 3D.

VIII Expression of HLIM

Expression of HLIM is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector, pSport,
20 previously used for the generation of the cDNA library is used to express HLIM in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

25 Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of HLIM into the bacterial growth media which can be used directly in the following assay for activity.

30 IX Demonstration of HLIM Activity

The binding of Zn^{2+} to HLIM is assayed by monitoring the resulting changes in enthalpy (heat production or absorption) in an isothermal titration microcalorimeter (Micro-Cal Inc., Northampton, MA). Titration microcalorimetry measurements do not require labeling of the ligand or receptor molecules; detection is based solely on the intrinsic change

5 in the heat of enthalpy upon binding. Multiple computer-controlled injections of a known volume of ZnCl_2 solution are directed into a thermally-controlled chamber containing HLIM. The change in enthalpy after each injection is plotted against the number of injections, producing a binding isotherm. The volumes and concentrations of the injected ZnCl_2 solution and of the HLIM solution are used along with the binding isotherm to calculate values for the
10 number, affinity, and association constant of HLIM with the Zn^{2+} ligand.

X Production of HLIM Specific Antibodies

HLIM that is substantially purified using PAGE electrophoresis (Sambrook, supra), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2, SEQ ID NO:4, or
15 SEQ ID NO:6 is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopolypeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (supra), and others.

20 Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested
25 for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

XI Purification of Naturally Occurring HLIM Using Specific Antibodies

Naturally occurring or recombinant HLIM is substantially purified by
30 immunoaffinity chromatography using antibodies specific for HLIM. An immunoaffinity column is constructed by covalently coupling HLIM antibody to an activated chromatographic resin, such as CnBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HLIM is passed over the immunoaffinity column, and the column

- 5 is washed under conditions that allow the preferential absorbance of HLIM (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HLIM binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and HLIM is collected.

XII Identification of Molecules Which Interact with HLIM

- 10 HLIM or biologically active fragments thereof are labeled with ^{125}I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HLIM, washed and any wells with labeled HLIM complex are assayed. Data obtained using different concentrations of HLIM are used to calculate values for the number, affinity, and association of HLIM with the
15 candidate molecules.

- All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection
20 with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: INCYTE PHARMACEUTICALS, INC.
- (ii) TITLE OF THE INVENTION: NOVEL HUMAN LIM PROTEINS
- (iii) NUMBER OF SEQUENCES: 11
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: US
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: Filed Herewith
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/739,485
 - (B) FILING DATE: 29-OCT-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Billings, Lucy J.
 - (B) REGISTRATION NUMBER: 36,749
 - (C) REFERENCE/DOCKET NUMBER: PF-0142 PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 650-855-0555
 - (B) TELEFAX: 650-845-4166

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 193 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY:
 - (B) CLONE: Consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met	Pro	Val	Trp	Gly	Gly	Gly	Asn	Lys	Cys	Gly	Ala	Cys	Gly	Arg	Thr	1	5	10	15
Val	Tyr	His	Ala	Glu	Glu	Val	Gln	Cys	Asp	Gly	Arg	Ser	Phe	His	Arg	20	25	30	
Cys	Cys	Phe	Leu	Cys	Met	Val	Cys	Arg	Lys	Asn	Leu	Asp	Ser	Thr	Thr	35	40	45	
Val	Ala	Ile	His	Asp	Glu	Glu	Ile	Tyr	Cys	Lys	Ser	Cys	Tyr	Gly	Lys	50	55	60	
Lys	Tyr	Gly	Pro	Lys	Gly	Tyr	Gly	Gln	Gly	Ala	Gly	Thr	Leu			65	70	75	80
Xaa	Met	Asp	Arg	Gly	Glu	Arg	Leu	Gly	Ile	Lys	Pro	Glu	Ser	Val	Gln	85	90	95	

```

Pro His Arg Pro Thr Thr Asn Pro Asn Xaa Ser Lys Phe Ala Gln Lys
      100      105      110
Tyr Gly Gly Ala Glu Lys Cys Ser Arg Cys Gly Asp Ser Val Tyr Ala
      115      120      125
Ala Glu Lys Ile Ile Gly Ala Gly Lys Pro Trp His Lys Asn Cys Phe
      130      135      140
Arg Cys Ala Lys Cys Gly Lys Ser Leu Glu Ser Thr Thr Leu Thr Glu
      145      150      155      160
Lys Glu Gly Glu Ile Tyr Cys Lys Gly Cys Tyr Ala Lys Asn Phe Gly
      165      170      175
Pro Lys Gly Phe Gly Phe Gly Gln Gly Ala Gly Ala Leu Val His Ser
      180      185      190
Glu

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 797 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:
- (B) CLONE: Consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CTGGACCCCTC	CCTCCAGCCC	AGCCTCGCTA	GCTCCGCCTG	CGGTACGTGC	TCCCGCCTCC	60
GACTCAAAAT	GCCTGTCTGG	GGAGGTGGAA	ACAAGTGTGG	GGCCTGTGGG	AGGACCGTGT	120
ACCACGCAGA	AGAGGTGCAG	TGTGATGGCA	GGAGCTTCCA	CCGCTGCTGC	TTTCTCTGCA	180
TGGTTTGCAG	GAAAAATTTA	GATAGCACAA	CAGTGGCAAT	TCACGATGAA	GAGATCTACT	240
GCAAATCCTG	CTACGGAAAG	AAGTATGGGC	CAAAAGGCTA	CGGTTATGGC	CAGGGCGCTG	300
GCACGCTTAA	MATGGACCGT	GGCGAGAGGC	TTGGCATCAA	ACCAGAGAGT	GTTCAGCCTC	360
ACAGGCCTAC	AACAAATCCA	AACAHTTCTA	AATTTGCTCA	GAAATATGGA	GGTGCTGAGA	420
AGTGTTCAG	ATGTGGGGAT	TCTGTATATG	CTGCCGAGAA	GATAATTGGA	GCTGGAAAGC	480
CCTGGCACAA	AAACTGTTTC	CGATGTGCAA	AGTGTGGGAA	GAGTCTTGAA	TCAACAACCTC	540
TGACTGAAAA	AGAAGGTGAG	ATTTACTGCA	AAGGATGTTA	TGCTAAAAAC	TTCCGGGCCCA	600
AGGGCTTTGG	TTTTGGGCAA	GGAGCTGGGG	CCTTGCTCCA	CTCTGAGTGA	GGCCACCATC	660
ACCCACCACA	CCCTGCCCCA	TCCTGCGCTT	TTCATCGCCA	TTCCATTCCC	AGCAGCTTTG	720
GAGACCTCCA	GGATTATTTT	TCTGTCAGCC	CTGCCACATA	TCACTAATGA	CTTGAACCTG	780
GGCATCTGGC	TCCCTTT					797

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 329 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:
- (B) CLONE: Consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Thr Thr Gln Gln Ile Asp Leu Gln Gly Pro Gly Pro Trp Gly Phe
 1      5      10      15
Arg Leu Val Gly Gly Lys Asp Phe Glu Gln Pro Leu Ala Ile Ser Arg
      20      25      30
Val Thr Pro Gly Ser Lys Ala Ala Leu Ala Asn Leu Cys Ile Gly Asp
      35      40      45

```

Val	Ile	Thr	Ala	Ile	Asp	Gly	Glu	Asn	Thr	Ser	Asn	Met	Thr	His	Leu
50						55					60				
Glu	Ala	Gln	Asn	Arg	Ile	Lys	Gly	Cys	Thr	Asp	Asn	Leu	Thr	Leu	Thr
65					70					75					80
Val	Ala	Arg	Ser	Glu	His	Lys	Val	Trp	Ser	Pro	Leu	Val	Thr	Glu	Glu
				85					90					95	
Gly	Lys	Arg	His	Pro	Tyr	Lys	Met	Asn	Leu	Ala	Ser	Glu	Pro	Gln	Glu
			100					105					110		
Val	Leu	His	Ile	Gly	Ser	Ala	His	Asn	Arg	Ser	Ala	Met	Pro	Phe	Thr
		115					120					125			
Ala	Ser	Pro	Ala	Ser	Ser	Thr	Thr	Ala	Arg	Val	Ile	Thr	Asn	Gln	Tyr
		130				135					140				
Asn	Asn	Pro	Ala	Gly	Leu	Tyr	Ser	Ser	Glu	Asn	Ile	Ser	Asn	Phe	Asn
145					150					155					160
Asn	Ala	Leu	Glu	Ser	Lys	Thr	Ala	Ala	Ser	Gly	Val	Glu	Ala	Asn	Ser
				165					170					175	
Arg	Pro	Leu	Asp	His	Ala	Gln	Pro	Pro	Ser	Ser	Leu	Val	Ile	Asp	Lys
			180					185					190		
Glu	Ser	Glu	Val	Tyr	Lys	Met	Leu	Gln	Glu	Lys	Gln	Glu	Leu	Asn	Glu
		195					200					205			
Pro	Pro	Lys	Gln	Ser	Thr	Ser	Phe	Leu	Val	Leu	Gln	Glu	Ile	Leu	Glu
		210				215					220				
Ser	Glu	Glu	Lys	Gly	Asp	Pro	Asn	Lys	Pro	Ser	Gly	Phe	Arg	Ser	Val
225				230						235					240
Lys	Ala	Pro	Val	Thr	Lys	Val	Ala	Ala	Ser	Ile	Gly	Asn	Ala	Gln	Lys
				245					250					255	
Leu	Pro	Met	Cys	Asp	Lys	Cys	Gly	Thr	Gly	Ile	Val	Gly	Val	Phe	Val
			260					265					270		
Lys	Leu	Arg	Asp	Arg	His	Arg	His	Pro	Glu	Cys	Tyr	Val	Cys	Thr	Asp
		275					280					285			
Cys	Gly	Thr	Asn	Leu	Lys	Gln	Lys	Gly	His	Phe	Phe	Val	Glu	Asp	Gln
	290					295					300				
Ile	Tyr	Cys	Glu	Lys	His	Ala	Arg	Glu	Arg	Val	Thr	Pro	Pro	Glu	Gly
305					310					315					320
Tyr	Glu	Val	Val	Thr	Val	Phe	Pro	Lys							
					325										

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1225 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:
- (B) CLONE: Consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GGCCCNNGCC	GCGCCGCTNT	NTCTCCNACA	NGCCGCGGGG	GGTGCCCTGC	AAGCTGTTCC	60
GCGCGTCTCTG	CCCGTCTGTC	CCCGCGGGGTC	GTCGCCCCGCC	ACAGCCGCGC	CATGACCACC	120
CAGCAGATAG	ACCTCCAGGG	CCCGGGGGCCG	TGGGGCTTCC	GCCTCGTGGG	CGGCAAGGAC	180
TTCGAGCAGC	CTCTCGCCAT	TTCCCGGGTC	ACTCCTGGAA	GCAAGGCGGC	TCTAGCTAAT	240
TTATGTATTG	GAGATGTAAT	CACAGCCATT	GATGGGGAAA	ATACTAGCAA	TATGACACAC	300
TTGGAAGCTC	AGAACAGAAT	CAAAGGCTGC	ACAGACAAC	TGACTCTCAC	TGTAGCCAGA	360
TCTGAACATA	AAGTCTGGTC	TCCTCTGGTG	ACGGAGGAAG	GGAAGCGTCA	TCCATACAAG	420
ATGAATTTAG	CCTCTGAACC	CCAGGAGGTC	CTGCACATAG	GAAGCGCCCA	CAACCGAAGT	480
GCCATGCCCT	TTACCGCCTC	GCCTGCCTCC	AGCACTACTG	CCAGGGTCAT	CACAAACCAG	540
TACAACAACC	CAGCTGGCCT	CTACTCTTCT	GAAAATATCT	CCAACTTCAA	CAATGCCCTG	600
GAGTCAAAGA	CTGCTGCCAG	CGGGGTGGAG	GCGAACAGCA	GACCCTTAGA	CCATGCTCAG	660
CCTCCAAGCA	GCCTTGTCAT	CGACAAAGAA	TCTGAAGTTT	ACAAGATGCT	TCAGGAGAAA	720
CAGGAGTTGA	ATGAGCCCC	GAAACAGTCC	ACGTCTTTCT	TGGTTTTGCA	GGAAATCCTG	780
GAGTCTGAAG	AAAAAGGGGA	TCCCAACAAG	CCCTCAGGAT	TCAGAAGTGT	TAAAGCTCCT	840
GTCATAAAG	TGGCTGCGTC	GATTGGAAAT	GCTCAGAAGT	TGCCTATGTG	TGACAAATGT	900
GGCACTGGGA	TTGTTGGTGT	GTTTGTGAAG	CTGCGGGACC	GTCACCGCCA	CCCTGAGTGT	960


```

TATGTSTGCA CTGACTGTGG CACCAACCTG AAACAGAAGG GCCATTTCTT TGTGGAGGAT 1020
CAAATCTACT GTGAGAAGCA TGCCCGGGAG CGAGTCACAC CACCTGAGGG TTATGAAGTG 1080
GTCAGTGTGT TCCCCAAGTG AGCCAGCAGA TCGACCACT GTTCTCCAGC AGGCCTCTGC 1140
TGCAGCTTTT TCTCTCAGTG TTCTGGCCCT CTCCTCTCTT GAAAGTTCTC TGCCTACTTT 1200
GGTTTTCCCT CTGCTTGTA AACTAT 1225

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 316 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY:
- (B) CLONE: Consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Met Pro Gln Thr Val Ile Leu Pro Gly Pro Ala Pro Trp Gly Phe Arg
 1          5          10          15
Leu Ser Gly Gly Ile Asp Phe Asn Gln Pro Leu Val Ile Thr Arg Ile
 20          25          30
Thr Pro Gly Ser Lys Ala Ala Ala Asn Leu Cys Pro Gly Asp Val
 35          40          45
Ile Leu Ala Ile Asp Gly Phe Gly Thr Glu Ser Met Thr His Ala Asp
 50          55          60
Ala Gln Asp Arg Ile Lys Ala Ala Ala His Gln Leu Cys Leu Lys Ile
 65          70          75          80
Asp Arg Gly Glu Thr His Leu Trp Ser Pro Gln Val Ser Glu Asp Gly
 85          90          95
Lys Ala His Pro Phe Lys Ile Asn Leu Glu Ser Glu Pro Gln Glu Phe
100          105          110
Lys Pro Ile Gly Thr Ala His Asn Arg Arg Ala Gln Pro Phe Val Ala
115          120          125
Ala Ala Asn Ile Asp Asp Lys Arg Gln Val Val Ser Ala Ser Tyr Asn
130          135          140
Ser Pro Ile Gly Leu Tyr Ser Thr Ser Asn Ile Gln Asp Ala Leu His
145          150          155          160
Gly Gln Leu Arg Gly Leu Ile Pro Ser Ser Pro Gln Asn Glu Pro Thr
165          170          175
Ala Ser Val Pro Pro Glu Ser Asp Val Tyr Arg Met Leu His Asp Asn
180          185          190
Arg Asn Glu Pro Thr Gln Pro Arg Gln Ser Gly Ser Phe Arg Val Leu
195          200          205
Gln Gly Met Val Asp Asp Gly Phe Asp Asp Arg Pro Ala Gly Thr Arg
210          215          220
Ser Val Arg Ala Pro Val Thr Lys Val His Gly Ser Gly Gly Ala
225          230          235          240
Gln Arg Met Pro Val Cys Asp Lys Cys Gly Ser Gly Ile Val Gly Ala
245          250          255
Val Val Lys Ala Arg Asp Lys Tyr Arg His Pro Glu Cys Phe Val Cys
260          265          270
Ala Asp Cys Asn Leu Asn Leu Lys Gln Lys Gly Tyr Phe Phe Ile Glu
275          280          285
Gly Glu Leu Tyr Cys Glu Thr His Ala Arg Ala Arg Thr Lys Pro Pro
290          295          300
Glu Gly Tyr Asp Thr Val Thr Leu Tyr Pro Lys Ala
305          310          315

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1336 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(A) LIBRARY:

(B) CLONE: Consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

CGGCTCGAGC GGCTCGAGGG CGCGGAGTGG CTGCCCTGCG CGGGGACACT CAGAGCCCGG      60
TGGGCGGGAG GAAGGCGGCA TGCCCCAGAC GGTGATCCTC CCGGGCCCTG CGCCCTGGGG      120
CTTCAGGCTC TCAGGGGGCA TAGACTTCAA CCAGCCTTTG GTCATCACCA GGATTACACC      180
AGGAAGCAAG GCGGCAGCTG CCAACCTGTG TCCTGGAGAT GTCATCCTGG CTATTGACGG      240
CTTTGGGACA GAGTCCATGA CTCATGCTGA TGCAGCAGGAC AGGATTAAAG CAGCAGCTCA      300
CCAGCTGTGT CTCAAAATTG ACAGGGGAGA AACTCACTTA TGGTCTCCAC AAGTATCTGA      360
AGATGGGAAA GCCCATCCTT TCAAAATCAA CTTAGAATCA GAACCACAGG AATTCAAACC      420
CATTGGTACC GCGCACACA GAAGGGCCCA GCCTTTTGTT GCAGCTGCAA ACATTGATGA      480
CAAAAGACAG GTAGTGAGCG CTTCTATAA CTCGCCAATT GGGCTCTATT CAACTAGCAA      540
TATACAAGAT GCGCTTCACG GACAGCTGCG GGGTCTCATT CCTAGCTCAC CTCAAAACGA      600
GCCCCACAGC TCGGTGCCCC CCGAGTCGGA CGTGTAACCG ATGCTCCACG ACAATCGGAA      660
TGAGCCCACA CAGCCTCGCC AGTCGGGCTC CTTCAGAGTG CTCCAGGGAA TGGTGGACGA      720
TGGGTTTGAT GACCGTCCGG CTGGAACGCG GAGTGTGAGA GCTCCGGTGA CGAAAGTCCA      780
TGGCGGTTCA GGCGGGGCAC AGAGGATGCC GGTCTGTGAC AAATGTGGGA GTGGCATAGT      840
TGGTGCTGTG GTGAAGGCGC GGGATAAGTA CCGGCACCTT GAGTGCTTCG TGTGTGCCGA      900
CTGCAACCTC AACCTCAAGC AAAAGGGCTA CTTCTTCATA GAAGGGGAGC TGTACTGCGA      960
AACCCACGCA AGAGCCCGCA CAAAGCCCCC AGAGGGCTAT GACACGGTCA CTCTGTATCC     1020
CAAAGCTTAA GTCTCTGCAG GCGTGGCACG CACGCACGCA CCCACCCACG CGCCACTTAC     1080
ACGAGAAGAC ATTCATGGCT TTGGGCAGAA GGATTGTGCA GATTGTCAAC TCCAAATCTA     1140
AAGTCAAGGC TTTAGACCTT TATCCTATTG TTTATTGAGG AAAAGGAATG GGAGGCAAAT     1200
GCCTGCTATG TGAAAAAAC ATACACTTAG CTATGTTTTG CAACTCTTTT TGGGGCTAGC     1260
AATAATGATA TTAAAGCAA TAATTTTTTG TATGTCATAC TCCACAATTT ACATGTATAT     1320
TACAGCCATC AAACAC

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 193 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 118161

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Met Pro Asn Trp Gly Gly Gly Lys Lys Cys Gly Val Cys Gln Lys Thr
 1          5          10          15
Val Tyr Phe Ala Glu Glu Val Gln Cys Glu Gly Asn Ser Phe His Lys
 20          25          30
Ser Cys Phe Leu Cys Met Val Cys Lys Lys Asn Leu Asp Ser Thr Thr
 35          40          45
Val Ala Val His Gly Glu Glu Ile Tyr Cys Lys Ser Cys Tyr Gly Lys
 50          55          60
Lys Tyr Gly Pro Lys Gly Tyr Gly Tyr Gly Gln Gly Ala Gly Thr Leu
 65          70          75          80
Ser Thr Asp Lys Gly Glu Ser Leu Gly Ile Lys His Glu Glu Ala Pro
 85          90          95
Gly His Arg Pro Thr Thr Asn Pro Asn Ala Ser Lys Phe Ala Gln Lys
100          105          110
Ile Gly Gly Ser Glu Arg Cys Pro Arg Cys Ser Gln Ala Val Tyr Ala
115          120          125
Ala Glu Lys Val Ile Gly Ala Gly Lys Ser Trp His Lys Ala Cys Phe
130          135          140
Arg Cys Ala Lys Cys Gly Lys Gly Leu Glu Ser Thr Thr Leu Ala Asp
145          150          155          160

```

Lys Asp Gly Glu Ile Tyr Cys Lys Gly Cys Tyr Ala Lys Asn Phe Gly
 165 170 175
 Pro Lys Gly Phe Gly Phe Gly Gln Gly Ala Gly Ala Leu Val His Ser
 180 185 190
 Glu

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 194 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 1234841

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Pro Asn Trp Gly Gly Gly Ala Lys Cys Gly Ala Cys Glu Lys Thr
 1 5 10 15
 Val Tyr His Ala Glu Glu Ile Gln Cys Asn Gly Arg Ser Phe His Lys
 20 25 30
 Thr Cys Phe His Cys Met Ala Cys Arg Lys Ala Leu Asp Ser Thr Thr
 35 40 45
 Val Ala Ala His Glu Ser Glu Ile Tyr Cys Lys Val Cys Tyr Gly Arg
 50 55 60
 Arg Tyr Gly Pro Lys Gly Ile Gly Tyr Gly Gln Gly Ala Gly Cys Leu
 65 70 75 80
 Ser Thr Asp Thr Gly Glu His Leu Gly Leu Gln Phe Gln Gln Ser Pro
 85 90 95
 Lys Pro Ala Arg Ser Val Thr Thr Ser Asn Pro Ser Lys Phe Thr Ala
 100 105 110
 Lys Phe Gly Glu Ser Glu Lys Cys Pro Arg Cys Gly Lys Ser Val Tyr
 115 120 125
 Ala Ala Glu Lys Val Met Gly Gly Gly Lys Pro Trp His Lys Thr Cys
 130 135 140
 Phe Arg Cys Ala Ile Cys Gly Lys Ser Leu Glu Ser Thr Asn Val Thr
 145 150 155 160
 Asp Lys Asp Gly Glu Leu Tyr Cys Lys Val Cys Tyr Ala Lys Asn Phe
 165 170 175
 Gly Pro Thr Gly Ile Gly Phe Gly Gly Leu Thr Gln Gln Val Glu Lys
 180 185 190
 Lys Glu

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 193 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 1314351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Pro Val Trp Gly Gly Gly Asn Lys Cys Gly Ala Cys Gly Arg Thr
 1 5 10 15
 Val Tyr His Ala Glu Glu Val Gln Cys Asp Gly Arg Thr Phe His Arg
 20 25 30
 Cys Cys Phe Leu Cys Met Val Cys Arg Lys Asn Leu Asp Ser Thr Thr
 35 40 45

```

Val Ala Ile His Asp Glu Glu Ile Tyr Cys Lys Ser Cys Tyr Gly Lys
 50          55          60
Lys Tyr Gly Pro Lys Gly Tyr Gly Tyr Gly Gln Gly Ala Gly Thr Leu
 65          70          75          80
Asn Met Asp Arg Gly Glu Arg Leu Gly Ile Lys Pro Glu Ser Ala Gln
          85          90          95
Pro His Arg Pro Thr Thr Asn Pro Asn Thr Ser Lys Phe Ala Gln Lys
          100          105          110
Tyr Gly Gly Ala Glu Lys Cys Ser Arg Cys Gly Asp Ser Val Tyr Ala
          115          120          125
Ala Glu Lys Ile Ile Gly Ala Gly Lys Pro Trp His Lys Asn Cys Phe
          130          135          140
Arg Cys Ala Lys Cys Gly Lys Ser Leu Glu Ser Thr Thr Leu Thr Glu
          145          150          155          160
Lys Glu Gly Glu Ile Tyr Cys Lys Gly Cys Tyr Ala Lys Asn Phe Gly
          165          170          175
Pro Lys Gly Phe Gly Tyr Gly Gln Gly Ala Gly Ala Leu Val His Ala
          180          185          190
Gln

```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 327 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 1020151

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```

Met Thr Thr Gln Gln Ile Val Leu Gln Gly Pro Gly Pro Trp Gly Phe
 1          5          10          15
Arg Leu Val Gly Gly Lys Asp Phe Glu Gln Pro Leu Ala Ile Ser Arg
          20          25          30
Val Thr Pro Gly Ser Lys Ala Ala Ile Ala Asn Leu Cys Ile Gly Asp
          35          40          45
Leu Ile Thr Ala Ile Asp Gly Glu Asp Thr Ser Ser Met Thr His Leu
          50          55          60
Glu Ala Gln Asn Lys Ile Lys Gly Cys Val Asp Asn Met Thr Leu Thr
          65          70          75          80
Val Ser Arg Ser Glu Gln Lys Ile Trp Ser Pro Leu Val Thr Glu Glu
          85          90          95
Gly Lys Arg His Pro Tyr Lys Met Asn Leu Ala Ser Glu Pro Gln Glu
          100          105          110
Val Leu His Ile Gly Ser Ala His Asn Arg Ser Ala Met Pro Phe Thr
          115          120          125
Ala Ser Pro Ala Pro Gly Thr Arg Val Ile Thr Asn Gln Tyr Asn Ser
          130          135          140
Pro Thr Gly Leu Tyr Ser Ser Glu Asn Ile Ser Asn Phe Asn Asn Ala
          145          150          155          160
Val Glu Ser Lys Thr Ser Ala Ser Gly Glu Glu Ala Asn Ser Arg Pro
          165          170          175
Ser Ala Gln Pro His Pro Ser Gly Gly Leu Ile Ile Asp Lys Glu Ser
          180          185          190
Glu Val Tyr Lys Met Leu Gln Glu Lys Gln Glu Leu Asn Glu Pro Pro
          195          200          205
Lys Gln Ser Thr Ser Phe Leu Val Leu Gln Glu Ile Leu Glu Ser Asp
          210          215          220
Gly Lys Gly Asp Pro Asn Lys Pro Ser Gly Phe Arg Ser Val Lys Ala
          225          230          235          240
Pro Val Thr Lys Val Ala Ala Ser Val Gly Asn Ala Gln Lys Leu Pro
          245          250          255

```

```

Ile Cys Asp Lys Cys Gly Thr Gly Ile Val Gly Val Phe Val Lys Leu
    260                265                270
Arg Asp His His Pro His Pro Glu Cys Tyr Val Cys Thr Asp Cys Gly
    275                280                285
Ile Asn Leu Lys Gln Lys Gly His Phe Phe Val Gly Asp Gln Ile Tyr
    290                295                300
Cys Glu Lys His Ala Arg Glu Arg Val Thr Pro Pro Glu Gly Tyr Asp
    305                310                315                320
Val Val Thr Val Phe Pro Lys
                325

```

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 330 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 887580

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```

Met Thr His Ala Val Thr Leu Arg Gly Pro Ser Pro Trp Gly Phe Arg
  1          5          10          15
Leu Val Gly Gly Arg Asp Phe Ser Ala Pro Leu Thr Ile Ser Arg Val
    20          25          30
His Ala Gly Ser Lys Ala Ala Leu Ala Leu Cys Pro Gly Asp Ser
    35          40          45
Ile Gln Ala Ile Asn Gly Glu Ser Thr Glu Leu Met Thr His Leu Glu
    50          55          60
Ala Gln Asn Arg Ile Lys Gly Cys His Asp His Leu Thr Leu Ser Val
    65          70          75          80
Ser Arg Pro Glu Asn Lys Asn Trp Pro Ser Ser Pro Asn Asp Lys Ala
    85          90          95
Gln Ala His Arg Ile His Ile Asp Pro Glu Ala Gln Asp Gly Ser Pro
    100         105         110
Ala Thr Ser Arg Arg Ser Ser Ile Ser Gly Ile Ser Leu Glu Asp Asn
    115         120         125
Arg Ser Gly Leu Gly Ser Pro Tyr Gly Gln Pro Pro Arg Leu Pro Val
    130         135         140
Pro His Asn Gly Ser Ser Asn Glu Val Thr Leu Pro Ser Gln Met Ser
    145         150         155         160
Ala Leu His Val Ser Pro Pro Pro Ser Ala Asp Thr Pro Arg Ile Leu
    165         170         175
Pro Arg Asn Arg Asp Cys Arg Val Asp Leu Gly Ser Glu Val Tyr Arg
    180         185         190
Met Leu Arg Glu Pro Ala Glu Pro Ala Ala Ser Glu Pro Lys Gln Ser
    195         200         205
Gly Ser Phe Arg Tyr Leu Gln Gly Met Leu Glu Ala Gly Glu Gly Gly
    210         215         220
Asp Arg Pro Gly Ser Gly Gly Ser Arg Asn Leu Lys Pro Ala Ala Ser
    225         230         235         240
Lys Leu Gly Ala Pro Leu Ser Gly Leu Gln Gly Leu Pro Glu Cys Thr
    245         250         255
Arg Cys Gly His Gly Ile Val Gly Thr Ile Val Lys Ala Arg Asp Lys
    260         265         270
Leu Tyr His Pro Glu Cys Phe Met Cys Ser Asp Cys Gly Leu Asn Leu
    275         280         285
Lys Gln Arg Gly Tyr Phe Phe Leu Asp Glu Arg Leu Tyr Cys Glu Asn
    290         295         300
His Ala Lys Ala Arg Val Lys Pro Pro Glu Gly Tyr Asp Val Val Ala
    305         310         315         320
Val Tyr Pro Asn Ala Lys Val Glu Leu Val
                325                330

```

- 5 What is claimed is:
1. A substantially purified human LIM protein comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.
 2. An isolated and purified polynucleotide sequence encoding the human LIM protein of claim 1.
 - 10 3. A polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 2.
 4. A hybridization probe comprising the polynucleotide sequence of claim 2.
 5. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or variants thereof.
 - 15 6. A polynucleotide sequence which is complementary to SEQ ID NO:2 or variants thereof.
 7. A hybridization probe comprising the polynucleotide sequence of claim 6.
 8. An expression vector containing the polynucleotide sequence of claim 2.
 9. A host cell containing the vector of claim 8.
 - 20 10. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment thereof, the method comprising the steps of:
 - a) culturing the host cell of claim 9 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
 - 25 11. A pharmaceutical composition comprising a substantially purified human LIM protein having an amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.
 12. A purified antibody which binds specifically to the polypeptide of claim 1.
 13. A purified agonist which specifically binds to and modulates the activity of the polypeptide of claim 1.
 - 30 14. A purified antagonist which specifically binds to and blocks the activity of the polypeptide of claim 1.
 15. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 11.

- 5 16. A method for detection of polynucleotides encoding the human LIM protein of claim 1 in a biological sample comprising the steps of:
- a) hybridizing a polynucleotide consisting of SEQ ID NO:2 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
 - b) detecting said hybridization complex, wherein the presence of said complex
- 10 correlates with the presence of a polynucleotide encoding human LIM protein in said biological sample.
17. The method of claim 16 wherein before hybridization, the nucleic acid material of the biological sample is amplified by the polymerase chain reaction.
18. A substantially purified human LIM protein comprising the amino acid sequence of
- 15 SEQ ID NO:3 or fragments thereof.
19. An isolated and purified polynucleotide sequence encoding the human LIM protein of claim 18.
20. A polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 19.
- 20 21. A hybridization probe comprising the polynucleotide sequence of claim 19.
22. An isolated and purified polynucleotide sequence comprising SEQ ID NO:4 or variants thereof.
23. A polynucleotide sequence which is complementary to SEQ ID NO:4 or variants thereof.
- 25 24. A hybridization probe comprising the polynucleotide sequence of claim 23.
25. An expression vector containing the polynucleotide sequence of claim 19.
26. A host cell containing the vector of claim 25.
27. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or a fragment thereof, the method comprising the steps of:
- 30 a) culturing the host cell of claim 26 under conditions suitable for the expression of the polypeptide; and
- b) recovering the polypeptide from the host cell culture.
28. A pharmaceutical composition comprising a substantially purified human LIM protein having an amino acid sequence of SEQ ID NO:3 in conjunction with a suitable

- 5 pharmaceutical carrier.
29. A purified antibody which binds specifically to the polypeptide of claim 18.
30. A purified agonist which specifically binds to and modulates the activity of the polypeptide of claim 18.
31. A purified antagonist which specifically binds to and blocks the activity of the polypeptide of claim 18.
- 10 32. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 28.
33. A method for detection of polynucleotides encoding the human LIM protein of claim 18 in a biological sample comprising the steps of:
- 15 a) hybridizing a polynucleotide consisting of SEQ ID NO:4 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
- b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding the human LIM protein in said biological sample.
- 20 34. The method of claim 33 wherein before hybridization, the nucleic acid material of the biological sample is amplified by the polymerase chain reaction.
35. A substantially purified human LIM protein comprising the amino acid sequence of SEQ ID NO:5 or fragments thereof.
36. An isolated and purified polynucleotide sequence encoding the human LIM protein of claim 35.
- 25 37. A polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 36.
38. A hybridization probe comprising the polynucleotide sequence of claim 36.
39. An isolated and purified polynucleotide sequence comprising SEQ ID NO:6 or variants thereof.
- 30 40. A polynucleotide sequence which is complementary to SEQ ID NO:6 or variants thereof.
41. A hybridization probe comprising the polynucleotide sequence of claim 40.

- 5 42. An expression vector containing the polynucleotide sequence of claim 36.
43. A host cell containing the vector of claim 42.
44. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:5 or a fragment thereof, the method comprising the steps of:
- 10 a) culturing the host cell of claim 43 under conditions suitable for the expression of the polypeptide; and
- b) recovering the polypeptide from the host cell culture.
45. A pharmaceutical composition comprising a substantially purified human LIM protein having an amino acid sequence of SEQ ID NO:5 in conjunction with a suitable pharmaceutical carrier.
- 15 46. A purified antibody which binds specifically to the polypeptide of claim 35.
47. A purified agonist which specifically binds to and modulates the activity of the polypeptide of claim 35.
48. A purified antagonist which specifically binds to and blocks the activity of the polypeptide of claim 35.
- 20 49. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 45.
50. A method for detection of polynucleotides encoding the human LIM protein of claim 35 in a biological sample comprising the steps of:
- a) hybridizing a polynucleotide consisting of SEQ ID NO:6 to nucleic acid material
- 25 of a biological sample, thereby forming a hybridization complex; and
- b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding the human LIM protein in said biological sample.
51. The method of claim 50 wherein before hybridization, the nucleic acid material of
- 30 the biological sample is amplified by the polymerase chain reaction.

5' CT GGA CCC TCC CTC CAG CCC AGC CTC GCT AGC TCC GCC TGC GGT AGG TGC TCC TCC
 9 18 27 36 45 54
 63 72 81 90 99 108
 CGC CTC CGA CTC AAA ATG CCT CTC TGG GGA GGT GGA AAC AAG TGT GGT GCC TGT
 M P V W G G N K C G A C
 117 126 135 144 153 162
 GGG AGG ACC GTG TAC CAC GCA GAA GAG GTG CAG TGT GAT GGC AGG AGC TTC CAC
 G R T V Y H A E E V Q C D G R S F H
 171 180 189 198 207 216
 CGC TGC TGC TTT CTC TGC ATG GTT TGC AGG AAA AAT TTA GAT AGC ACA ACA GTG
 R C C F L C M V C R K N L D S T T V
 225 234 243 252 261 270
 GCA ATT CAC GAT GAA GAG ATC TAC TGC AAA TCC TGC TAC GGA AAG AAG TAT GGG
 A I H D E E I Y C C K S C Y G K K Y G
 279 288 297 306 315 324
 CCA AAA GGC TAC GGT TAT GGC CAG GGC GCT GGC ACG CTT AAM ATG GAC CGT GGC
 P K G Y G Y G Q G A G T L X M D R G
 333 342 351 360 369 378
 GAG AGG CTT GGC ATC AAA CCA GAG AGT GTT CAG CCT CAC AGG CCT ACA ACA AAT
 E R L G I K P E S V Q P H R P T T N

FIGURE 1A

2/29

387	396	405	414	423	432
CCA AAC AHT TCT AAA TTT GCT CAG AAA TAT GGA GGT GCT GAG AAG TGT TCC AGA					
P N X S K F A Q K Y G G A E K C S R					
441	450	459	468	477	486
TGT GGG GAT TCT GTA TAT GCT GCC GAG AAG ATA ATT GGA GCT GGA AAG CCC TGG					
C G D S V Y A A E K I I G A G K P W					
495	504	513	522	531	540
CAC AAA AAC TGT TTC CGA TGT GCA AAG TGT GGG AAG AGT CTT GAA TCA ACA ACT					
H K N C F R C A K C G K S L E S T T					
549	558	567	576	585	594
CTG ACT GAA AAA GAA GGT GAG ATT TAC TGC AAA GGA TGT TAT GCT AAA AAC TTC					
L T E K E G E I Y C K G C Y A K N F					
603	612	621	630	639	648
GGG CCC AAG GGC TTT GGT TTT GGG CAA GGA GCT GGG GCC TTG GTC CAC TCT GAG					
G P K G G F G F G Q G A G A L V H S E					
657	666	675	684	693	702
TGA GGC CAC CAT CAC CCA CAC CCT GCC CAC TCC TGC GCT TTT CAT CGC CAT					
711	720	729	738	747	756
TCC ATT CCC AGC AGC TTT GGA GAC CTC CAG GAT TAT TTC TCT GTC AGC CCT GCC					
765	774	783	792		
ACA TAT CAC TAA TGA CTT GAA CTT GGG CAT CTG GCT CCC TTT 3'					

FIGURE 1B

3/29

```

          9      18      27      36      45      54
5' GGC CCN NGC CGC GCC GCT NTN TCT CCN ACA NGC CGC GGG TGC CCT GCA AGC

          63      72      81      90      99      108
TGT TCC GCG CGT CCT GCC CGT CTG TCC CCG CGG GTC GTC GCC CGC CAC AGC CGC

          117      126      135      144      153      162
GCC ATG ACC ACC CAG CAG ATA GAC CTC CAG GGC CCG GGG TGG GGC TTC CGC
M T T Q Q I D L Q G P G P W G F R

          171      180      189      198      207      216
CTC GTG GGC AAG GAC TTC GAG CAG CCT CTC GCC ATT TCC CGG GTC ACT CCT
L V G G K D F E Q P L A I S R V T P

          225      234      243      252      261      270
GGA AGC AAG GCG GCT CTA GCT AAT TTA TGT ATT GGA GAT GTA ATC ACA GCC ATT
G S K A A L A N L C I G D V I T A I

          279      288      297      306      315      324
GAT GGG GAA AAT ACT AGC AAT ATG ACA CAC TTG GAA GCT CAG AAC AGA ATC AAA
D G E N T S N M T H L E A Q N R I K

          333      342      351      360      369      378
GGC TGC ACA GAC AAC TTG ACT CTC ACT GTA GCC AGA TCT GAA CAT AAA GTC TGG
G C T D N L L T L T V A R S E H K V W

```

FIGURE 2A

4/29

387	396	405	414	423	432
TCT CCT CTG GTG ACG GAG GAA GGG AAG CGT CAT CCA TAC AAG ATG AAT TTA GCC					
S P L V T E E G K R H P Y K M N L A					
441	450	459	468	477	486
TCT GAA CCC CAG GAG GTC CTG CAC ATA GGA AGC GCC CAC AAC CGA AGT GCC ATG					
S E P Q E V L H I G S A H N R S A M					
495	504	513	522	531	540
CCC TTT ACC GCC TCG CCT GGC CTC TCC TCC AGC ACT ACT ACT GTC ATC ACA AAC CAG					
P F T A S P A S S S T T A R V I T N Q					
549	558	567	576	585	594
TAC AAC AAC CCA GCT GGC CTC TAC TCT TCT GAA AAT ATC TCC AAC TTC AAC AAT					
Y N N P A G L Y S S E N I S N F N N					
603	612	621	630	639	648
GCC CTG GAG TCA AAG ACT GCT GCC AGC GCG GTG GAG GCG AAC AGC AGA CCC TTA					
A L E S K T A A S G V E A N S R P L					
657	666	675	684	693	702
GAC CAT GCT CAG CCT CCA AGC AGC AGC CTT GTC ATC GAC AAA GAA TCT GAA GTT TAC					
D H A Q P P S S L V I D K E S E V Y					
711	720	729	738	747	756
AAG ATG CTT CAG GAG AAA CAG GAG TTG AAT GAG CCC CCG AAA CAG TCC ACG TCT					
K M L Q E K Q E L N E P P K Q S T S					

FIGURE 2B

5/29

765	774	783	792	801	810
TTC TTG GTT TTG CAG GAA ATC CTG GAG TCT GAA GAA GGG GAT CCC AAC AAG					
F L V L Q E I L E S E E K G D P N K					
819	828	837	846	855	864
CCC TCA GGA TTC AGA AGT GTT AAA GCT CCT GTC ACT AAA GTG GCT GCG TCG ATT					
P S G G F R S V K A P V T K V A A S I					
873	882	891	900	909	918
GGA AAT GCT CAG AAG TTG CCT ATG TGT GAC AAA TGT GGC ACT GGG ATT GTT GGT					
G N A Q K L P M C D K C G T G I V G					
927	936	945	954	963	972
GTG TTT GTG AAG CTG CGG GAC CGT CAC CGC CAC CCT GAG TGT TAT GTG TGC ACT					
V F V K L R D R H R H P E C Y V C T					
981	990	999	1008	1017	1026
GAC TGT GGC ACC AAC CTG AAA CAG AAG GGC CAT TTC TTT GTG GAG GAT CAA ATC					
D C G T N L K Q K G H F F V E D Q I					
1035	1044	1053	1062	1071	1080
TAC TGT GAG AAG CAT GCC CGG GAG CGA GTC ACA CCA CCT GAG GGT TAT GAA GTG					
Y C E K H A R E R V T P P E G Y E V					
1089	1098	1107	1116	1125	1134
GTC ACT GTG TTC CCC AAG TGA GCC AGC AGA TCY GAC CAC TGT TCT CCA GCA GGC					
V T V F P K					

FIGURE 2C

1143	1152	1161	1170	1179	1188
CTC TGC TGC AGC TTT TTC TCT TCT CAG TGT TCT GGC CCT CTC CTC TCT TGA AAG TTC					
1197	1206	1215	1224		
TCT GCC TAC TTT GGT TTT CCC TCT GCT TGT AAA ACA T 3'					

7/29

5' 9 18 27 36 45 54
 C GGC TCG AGC GGC TCG AGG GCG CGG AGT GGC TGC CCT GCG CGG GGA CAC TCA

63 72 81 90 99 108
 GAG CCC GGT GGG CGG GAG GAA GGC GGC ATG CCC CAG ACG GTG ATC CTC CCG GGC
 M P Q T V I L P G

117 126 135 144 153 162
 CCT GCG CCC TGG GGC TTC AGG CTC TCA GGG GGC ATA GAC TTC AAC CAG CCT TTG
 P A P W G F R L S G G I D F N Q P L

171 180 189 198 207 216
 GTC ATC ACC AGG ATT ACA CCA GGA AGC AAG GCG GCA GCT GCC AAC CTG TGT CCT
 V I T R I T P G S K A A A A N L C P

225 234 243 252 261 270
 GGA GAT GTC ATC CTG GCT ATT GAC GGC TTT GGG ACA GAG TCC ATG ACT CAT GCT
 G D V I L A I D G F G T E S M T H A

279 288 297 306 315 324
 GAT GCG CAG GAC AGG ATT AAA GCA GCA GCT CAC CAG CTG TGT CTC AAA ATT GAC
 D A Q D R I K A A A H Q L C L K I D

333 342 351 360 369 378
 AGG GGA GAA ACT CAC TTA TGG TCT CCA CAA GTA TCT GAA GAT GGG AAA GCC CAT
 R G E T H L W S P Q V S E D G K A H

FIGURE 3A

8/29

387	396	405	414	423	432
CCT TTC AAA ATC AAC TTA GAA TCA GAA CCA CAG GAA TTC AAA CCC ATT GGT ACC					
P F K I N L E S E P Q E F K P I G T					
441	450	459	468	477	486
GCG CAC AAC AGA AGG GCC CAG CCT TTT GTT GCA GCT GCA AAC ATT GAT GAC AAA					
A H N R R A Q P F V A A A N I D D K					
495	504	513	522	531	540
AGA CAG GTA GTG AGC GCT TCC TAT AAC TCG CCA ATT GGG CTC TAT TCA ACT AGC					
R Q V V S A S Y N S P I G L Y S T S					
549	558	567	576	585	594
AAT ATA CAA GAT GCG CTT CAC GGA CAG CTG CGG GGT CTC ATT CCT AGC TCA CCT					
N I Q D A L H G Q L R G L I P S S P					
603	612	621	630	639	648
CAA AAC GAG CCC ACA GCC TCG GTG CCC CCC GAG TCG GAC GTG TAC CGG ATG CTC					
Q N E P T A S V P P E S D V Y R M L					
657	666	675	684	693	702
CAC GAC AAT CGG AAT GAG CCC ACA CAG CCT CGC CAG TCG GGC TCC TTC AGA GTG					
H D N R N E P T Q P R Q S G S F R V					
711	720	729	738	747	756
CTC CAG GGA ATG GTG GAC GAT GGG TTT GAT GAC CGT CCG GCT GGA ACG CGG AGT					
L Q G M V D D G G F D D R P A G T R S					

FIGURE 3B

9/29

765	774	783	792	801	810
GTG AGA GCT CCG GTG ACG AAA GTC CAT GGC GGT TCA GGC GGG GCA CAG AGG ATG					
V R A P V T K V H G G S G A Q R M					
819	828	837	846	855	864
CCG GTC TGT GAC AAA TGT GGG AGT GGC ATA GTT GGT GCT GTG AAG GCG CGG					
P V C D K C G S G I V G A V K A R					
873	882	891	900	909	918
GAT AAG TAC CCG CAC CCT GAG TGC TTC GTG TGT GCC GAC TGC AAC CTC AAC CTC					
D K Y R H P E C F V C A D C N L L					
927	936	945	954	963	972
AAG CAA AAG GGC TAC TTC TTC ATA GAA GGG GAG CTG TAC TGC GAA ACC CAC GCA					
K Q K G Y F F I E G E L Y C E T H A					
981	990	999	1008	1017	1026
AGA GCC CGC ACA AAG CCC CCA GAG GGC TAT GAC ACG GTC ACT CTG TAT CCC AAA					
R A R T K P P E G Y D T V T L Y P K					
1035	1044	1053	1062	1071	1080
GCT TAA GTC TCT GCA GGC GTG GCA CGC ACG CAC GCA CCC ACC CAC GCG CCA CTT					
A					
1089	1098	1107	1116	1125	1134
ACA CGA GAA GAC ATT CAT GGC TTT GGG CAG AAG GAT TGT GCA GAT TGT CAA CTC					

FIGURE 3C

10/29

1143	1152	1161	1170	1179	1188
CAA ATC TAA AGT CAA GGC TTT AGA CCT TTA TCC TAT TGT TTA TTG AGG AAA AGG					
1197	1206	1215	1224	1233	1242
AAT GGG AGG CAA ATG CCT GCT ATG TGA AAA AAA CAT ACA CTT AGC TAT GTT TTG					
1251	1260	1269	1278	1287	1296
CAA CTC TTT TTG GGG CTA GCA ATA ATG ATA TTT AAA GCA ATA ATT TTT TGT ATG					
1305	1314	1323	1332		
TCA TAC TCC ACA ATT TAC ATG TAT ATT ACA GCC ATC AAA CAC 3'					

FIGURE 3D

1	MPVWGGGNKCGACGRTVYHAEDEVQCCDGRSFHRCCFLCMVC	HLIM-1
1	MPNWWGGGKKCCGVCKQKCTVYVEAEDEVQCCDGRSFHRCCFLCMVC	GI 118161
1	MPNWWGGGAKCCGACCEKCTVYHAEDEVQCCDGRSFHRCCFLCMVC	GI 1234841
1	MPVWGGGNKCGACGRTVYHAEDEVQCCDGRSFHRCCFLCMVC	GI 1314351
41	RKNLDSSTVAIHDEEIIYCKSKSCYGGKKYGGYGGQAGT	HLIM-1
41	RKNLDSSTVAIVHGEIIYCKSKSCYGGKKYGGYGGQAGT	GI 118161
41	RKALLDSTTVAIAHESIIYCKSKSCYGGRRYGGYGGQAGT	GI 1234841
41	RKNLDSSTVAIHDEEIIYCKSKSCYGGKKYGGYGGQAGT	GI 1314351
81	XMDRGERLGIIK-PESVQPHRRPTTNP	HLIM-1
81	STDKGEHSLGIIK-HEEAPGHRRPTTNP	GI 118161
81	STDKGEHSLGIIK-LQFQQSSPKPARSVTTNP	GI 1234841
81	NMDRGERLGIIK-PESAQPHRRPTTNP	GI 1314351
120	SRCGDSVYAAEKIIGAGKPVWHKNCFRCAKCGKSL	HLIM-1
120	PRCSQAQVYAAEKVIGAGKSWHKAACFRCAKCGKSL	GI 118161
121	PRCGKSVYAAEKVMGGGKPVWHKTCFRCAKCGKSL	GI 1234841
120	SRCGDSVYAAEKIIGAGKPVWHKNCFRCAKCGKSL	GI 1314351
160	EKEGEIYCKGCIYAKNFGPKGFGGQAGALVHSE	HLIM-1
160	DKDGEIYCKGCIYAKNFGPKGFGGQAGALVHSE	GI 118161
161	DKDGEIYCKGCIYAKNFGPKGFGGQAGALVHSE	GI 1234841
160	EKEGEIYCKGCIYAKNFGPKGFGGQAGALVHQAQ	GI 1314351

FIGURE 4

1 MT T Q Q I D L Q G P G P W G F R L V G G K D F E Q P L A I S R V T P G S K A A HLM-2
1 MT T Q Q I V L Q G P G P W G F R L V G G K D F E Q P L A I S R V T P G S K A A GI 1020151
1 MT - H A V T L R G P S P W G F R L V G G R D F S A P L T I S R V H A G S K A A GI 887580

41 L A N L C I G D V I T A I D G E N T S N M T H L E A Q N R I K G C T D N L T L T HLM-2
41 I A N L C I G D L I T A I D G E D T S S M T H L E A Q N K I K G C V D N M T L T GI 1020151
40 L A A L C P G D S I Q A I N G E S T E L M T H L E A Q N R I K G C H D H L T L S GI 887580

81 V A R S E H K V W S P L V T E E G K R H P Y K M N L A S E P Q E V L H I G S A H HLM-2
81 V S R S E Q K I W S P L V T E E G K R H P Y K M N L A S E P Q E V L H I G S A H GI 1020151
80 V S R P E N K N W P S - - S P N D K A Q A H R I H I D P E A Q D - - - G S P A GI 887580

121 N R S A M P F T A S P A S S T T A R V I T N Q Y N N P A G L Y S S E N I S N F N HLM-2
121 N R S A M P F T A S P A P G T - - R V I T N Q Y N S P T G L Y S S E N I S N F N GI 1020151
114 T S R R S S I S G I S L E D N R S - G L G S P Y G Q P P R L P V P H N G S S N E GI 887580

161 N A L E S K T A A S G V E A N S R P L D H A Q P P S S L V I D K E - - - - S HLM-2
159 N A V E S K T S A S G E E A N S R P S A Q P H P S G G L I I D K E - - - - S GI 1020151
153 V T L P S Q M S A - - - - L H V S P P P S A D T P R I L P R N R D C R V D L G S GI 887580

195 E V Y K M L Q E K Q E L N E P - P K Q S T S F L V L Q E I L E S E E K G D P N K HLM-2
193 E V Y K M L Q E K Q E L N E P - P K Q S T S F L V L Q E I L E S D G K G D P N K GI 1020151
189 E V Y R M L R E P A E P A A S E P K Q S G S F R Y L Q G M L E A G E G C D R P G GI 887580

FIGURE 5A

234	P	S	G	F	R	S	V	K	A	P	V	T	K	V	A	A	S	I	G	N	A	Q	K	L	P	M	C	D	K	C	G	T	G	I	V	G	V	F	V	K	HLIM-2
232	P	S	G	F	R	S	V	K	A	P	V	T	K	V	A	A	S	V	G	N	A	Q	K	L	P	I	C	D	K	C	G	T	G	I	V	G	V	F	V	K	GI 1020151
229	S	G	F	R	S	V	K	A	P	V	T	K	V	A	A	S	P	L	S	G	L	Q	G	L	P	E	C	T	R	C	G	H	G	I	V	G	T	I	V	K	GI 887580
274	L	R	D	R	H	R	H	P	E	C	Y	V	C	T	D	C	G	T	N	L	K	Q	K	G	H	F	F	V	E	D	Q	I	Y	C	E	K	H	A	R	E	HLIM-2
272	L	R	D	H	H	P	H	P	E	C	Y	V	C	T	D	C	G	I	N	L	K	Q	K	G	H	F	F	V	G	D	Q	I	Y	C	E	K	H	A	R	E	GI 1020151
269	A	R	D	K	L	Y	H	P	E	C	F	M	C	S	D	C	G	L	N	L	K	Q	R	G	Y	F	F	L	D	E	R	L	Y	C	E	N	H	A	K	A	GI 887580
314	R	V	T	P	P	E	G	Y	E	V	V	T	V	F	F	P	K																								HLIM-2
312	R	V	T	P	P	E	G	Y	D	V	V	T	V	F	F	P	K																							GI 1020151	
309	R	V	K	P	P	E	G	Y	D	V	V	A	V	Y	P	N	A	K	V	E	L	V																	GI 887580		

FIGURE 5B

14/29

1	M	P	-	Q	T	V	I	L	P	G	P	A	P	W	G	F	R	L	S	G	G	I	D	F	N	Q	P	L	V	I	T	R	I	T	P	G	S	K	A	A	HLIM-3
1	M	T	Q	Q	I	V	L	Q	G	P	G	P	W	G	F	R	L	V	G	G	K	D	F	E	Q	P	L	A	I	S	R	V	T	P	G	S	K	A	A	GI 1020151	
1	M	-	T	H	A	V	T	L	R	G	P	S	P	W	G	F	R	L	V	G	G	R	D	F	S	A	P	L	T	I	S	R	V	H	A	G	S	K	A	GI 887580	
40	A	A	N	L	C	P	G	D	V	I	L	A	I	D	G	F	G	T	E	S	M	T	H	A	D	A	Q	D	R	I	K	A	A	H	Q	L	C	L	K	HLIM-3	
41	I	A	N	L	C	I	G	D	L	I	T	A	I	D	G	E	D	T	S	S	M	T	H	L	E	A	Q	N	K	I	K	G	C	V	D	N	M	T	L	T	GI 1020151
40	L	A	A	L	C	P	G	D	S	I	Q	A	I	N	G	E	S	T	E	L	M	T	H	L	E	A	Q	N	R	I	K	G	C	H	D	H	L	T	L	S	GI 887580
80	I	D	R	G	E	T	H	L	W	S	P	Q	V	S	E	D	G	K	A	H	P	F	K	I	N	L	E	S	E	P	Q	E	F	K	P	I	G	T	A	H	HLIM-3
81	V	S	R	S	E	Q	K	I	W	S	P	L	V	T	E	E	G	K	R	H	P	Y	K	M	N	L	A	S	E	P	Q	E	V	L	H	I	G	S	A	H	GI 1020151
80	V	S	R	P	E	N	K	N	W	P	S	-	S	P	N	D	K	A	Q	A	H	R	I	H	I	D	P	E	A	Q	D	G	S	P	A	T	S	R	R	GI 887580	
120	N	R	R	A	Q	P	F	V	A	A	N	I	D	D	K	R	Q	V	V	S	A	S	Y	N	S	P	I	G	L	Y	S	T	S	N	I	-	-	-	Q	HLIM-3	
121	N	R	S	A	M	P	F	T	A	S	P	A	P	G	T	R	-	V	I	T	N	Q	Y	N	S	P	T	G	L	Y	S	S	E	N	I	S	N	F	N	GI 1020151	
118	S	S	-	-	-	I	S	G	I	S	L	E	D	N	R	S	G	L	G	S	P	Y	G	Q	P	P	R	L	P	V	P	H	N	G	S	S	N	E	GI 887580		
157	D	A	L	H	G	Q	L	R	G	L	-	-	-	-	I	P	S	S	P	Q	N	E	P	T	A	S	-	-	V	P	P	E	-	-	-	-	-	-	S	HLIM-3	
159	N	A	V	E	S	K	T	S	A	S	G	E	E	A	N	S	R	P	S	A	Q	P	H	P	S	G	G	L	I	I	D	K	E	-	-	-	-	-	-	S	GI 1020151
153	V	T	L	P	S	Q	M	S	A	L	-	-	-	-	H	V	S	P	P	P	S	A	D	T	P	R	I	L	P	R	N	R	D	C	R	V	D	L	G	S	GI 887580
184	D	V	Y	R	M	L	H	D	N	R	N	-	E	P	T	Q	P	R	Q	S	G	S	F	R	V	L	Q	G	M	V	D	D	-	-	-	G	F	D	D	R	HLIM-3
193	E	V	Y	K	M	L	Q	E	K	Q	E	-	L	N	E	P	P	K	Q	S	T	S	F	L	V	L	Q	E	I	L	E	S	D	G	K	G	D	P	N	K	GI 1020151
189	E	V	Y	R	M	L	R	E	P	A	E	P	A	A	S	E	P	K	Q	S	G	S	F	R	Y	L	Q	G	M	L	E	A	G	E	G	G	D	R	P	G	GI 887580

FIGURE 6A

15/29

220	P	A	G	T	R	S	V	R	A	P	V	T	K	V	H	G	G	S	G	G	A	Q	R	M	P	V	C	D	K	C	G	S	G	I	V	G	A	V	V	K	HLIM-3	
232	P	S	G	F	R	S	V	K	A	P	V	T	K	V	A	A	S	V	G	N	A	Q	K	L	P	I	C	D	K	C	G	T	G	I	V	G	V	F	V	K	GI 1020151	
229	S	G	G	S	R	N	L	K	P	A	A	S	K	L	G	A	P	L	S	G	L	Q	G	L	P	E	C	T	R	C	G	H	G	I	V	G	T	I	V	K	GI 887580	
260	A	R	D	K	Y	R	H	P	E	C	F	V	C	A	D	C	N	L	N	L	K	Q	K	G	Y	F	F	I	E	G	E	L	Y	C	E	T	H	A	R	A	HLIM-3	
272	L	R	D	H	H	P	H	P	E	C	Y	V	C	T	D	C	G	I	N	L	K	Q	K	G	H	F	F	V	G	D	Q	I	Y	C	E	K	H	A	R	E	GI 1020151	
269	A	R	D	K	L	Y	H	P	E	C	F	M	C	S	D	C	G	L	N	L	K	Q	R	G	Y	F	F	L	D	E	R	L	Y	C	E	N	H	A	K	A	GI 887580	
300	R	T	K	P	P	E	G	Y	D	T	V	T	L	Y	P	K	A																									HLIM-3
312	R	V	T	P	P	E	G	Y	D	V	V	T	V	F	P	K																									GI 1020151	
309	R	V	K	P	P	E	G	Y	D	V	V	A	V	Y	P	N	A	K	V	E	L	V																			GI 887580	

FIGURE 6B

16/29




FIGURE 7

17/29




FIGURE 8

18/29




FIGURE 9

19/29




FIGURE 10

20/29




FIGURE 11

21/29

Library	Lib Description	Abun	Pct Abun
HEARNOT01	heart, 56 M	4	0.2851
BLADNOT03	bladder, 80 F, match to BLADTUT02	4	0.1084
BRAINOT09	brain, fetal M	2	0.0524
PROSNOT14	prostate, 60 M, match to PROSTUT08	2	0.0512
PLACNOM03	placenta, fetal, NORM, WM	1	0.0363
PROSNOT06	prostate, 57 M, match to PROSTUT04	3	0.0343
SPLNFEM01	spleen, fetal, WM	1	0.0332
FIBRSEM01	fibroblasts, senescent, NORM, WM	1	0.0310
BRAITUT03	brain tumor, astrocytoma, 17 F	2	0.0308
BLADTUT02	bladder tumor, 80 F, match to BLADNOT03	1	0.0305
LUNGFEM01	lung, fetal, NORM, WM	2	0.0296
BRAITUT12	brain tumor, astrocytoma, 40 F, match to BRAINOT14	1	0.0272
URETTUT01	ureter tumor, 69 M	1	0.0262
BLADTUT04	bladder tumor, 60 M, match to BLADNOT05	2	0.0253
LIVRNOT01	liver, 49 M	1	0.0198
THYMNOT02	thymus, 3 M	1	0.0194
BRAINOT03	brain, 26 M	1	0.0185
HNT2NOT01	hNT2 cell line, teratocarcinoma, control	1	0.0173
BRAITUT02	brain tumor, metastasis, 58 M	1	0.0170
SINTBST01	small intestine, ileum, Crohn's, 18 F	1	0.0168
UTRSNOT02	uterus, 34 F	1	0.0167
BRSTNOT03	breast, 54 F, match to BRSTTUT02	1	0.0147
THYRNOT03	thyroid tumor, adenoma, 28 F	1	0.0138
LATRUT02	heart tumor, myoma, 43 M	1	0.0137
CARDFEM01	heart, fetal, NORM, WM	1	0.0112

FIGURE 12

22/29

Library	Lib Description	Abun	Pct Abun
OVARNON01	ovary, 59 F, NORM	5	0.7974
BRSTNOT01	breast, 56 F	37	0.7129
PLACNOT02	placenta, fetal F	30	0.5038
SYNORAT01	synovium, elbow, rheumatoid, 51 F	9	0.4300
LUNGNOM01	lung, 72 M, WM	15	0.4009
UTRSNOT02	uterus, 34 F	24	0.3999
MUSCNOT02	muscle, psoas, 12 M	10	0.3855
SYNORAB01	synovium, hip, rheumatoid, 68 F	19	0.3710
LUNGNOT02	lung, 47 M	15	0.3686
RATRNOT01	heart, right atrium, 51 F	4	0.3497
OVARNOT02	ovary, 59 F	11	0.3472
SYNOOAT01	synovium, knee, osteoarthritis, 82 F	19	0.3417
LUNGNOT01	lung, 72 M	10	0.3381
PGANNON02	paraganglionic tumor, benign paraganglioma, 46 M, NORM	3	0.3209
THYRNOT01	thyroid, 64 F	14	0.3207
LATRNOT01	heart, left atrium, 51 F	12	0.3192
KIDNNOT01	kidney, 64 F	2	0.3155
UTRSNOT01	uterus, 59 F	8	0.3148
SYNORAT05	synovium, knee, rheumatoid, 62 F	11	0.3147
SKINBIT01	skin, leg, erythema nodosum	12	0.3071
PANCNOT07	pancreas, fetal M	10	0.2866
MYOMNOT01	uterus, myometrium, 43 F	7	0.2863
LUNGNOT09	lung, fetal M	10	0.2858
HEARNOT01	heart, 56 M	4	0.2851
FIBRNOT01	WI38 lung fibroblast cell line, fetal F	6	0.2813

FIGURE 13A

23/29

BLADNOT01	bladder, 78 F	8	0.2802
PLACNOB01	placenta, neonatal F	11	0.2765
BRSTNOT03	breast, 54 F, match to BRSTTUT02	18	0.2643
COLNNOT27	large intestine, cecum, Crohn's, 31 M	4	0.2505
FIBRSEM01	fibroblasts, senescent, NORM, WM	8	0.2478
LUNGAST01	lung, asthma, 17 M	25	0.2360
MPHGNOT03	macrophages (adher PBMNC), M/F	18	0.2328
PANCNOT08	pancreas, 65 F, match to PANCNTUT01	9	0.2285
LUNGNOT12	lung, 78 M	8	0.2223
OVARNOT07	ovary, 28 F	8	0.2152
RATRNOT02	heart, right atrium, 39 M	9	0.2134
ADRENOT01	adrenal gland, 10-46 M/F	2	0.2103
LVENNOT02	heart, left ventricle, 39 M	1	0.2096
CONNNOT01	fat, mesentary, 71 M	14	0.2083
BRSTNOT05	breast, 58 F, match to BRSTTUT03	13	0.2008
CORNNOT01	corneal fibroblasts, 76y	2	0.1998
UTRSNOT05	uterus, 45 F	7	0.1946
BLADTUT07	bladder, microfoci tumor, 58 M	7	0.1943
COLNNOT01	colon, 75 M, match to COLNTUT02	9	0.1919
SINTTUT01	small intestine tumor, 42 M	5	0.1908
COLNCRT01	colon, Crohn's, 40 M, match to COLNNOT05	4	0.1874
BLADNOT06	bladder, 66 M, match to BLADTUT05	7	0.1868
BRSTNOM02	breast, F, NORM, WM	9	0.1858
COLNFET02	colon, fetal F	13	0.1857
STOMNOT02	stomach, 52 M, match to STOMTUT01	6	0.1846
BRSTNOT07	breast, 43 F	6	0.1843
FIBRNOT02	GD23A fibroblasts, control	1	0.1838
URETTUT01	ureter tumor, 69 M	7	0.1832
LVENNOT01	heart, left ventricle, 51 F	4	0.1816

FIGURE 13B

24/29

THP1PLB01	THP-1 promonocyte cell line, treated PMA, LPS	4	0.1809
LUNGNOT03	lung, 79 M, match to LUNGUT02	9	0.1803
BLADTUT04	bladder tumor, 60 M, match to BLADNOT05	14	0.1773
PROSTUT03	prostate tumor, 67 M, match to PROSNOT05	5	0.1761
SYNORAT04	synovium, wrist, rheumatoid, 62 F	10	0.1741
SINTNOT02	small intestine, 55 F	5	0.1729
BRSTNOT04	breast, 62 F	18	0.1728
COLNNOT08	colon, 60 M	4	0.1703
SYNORAT03	synovium, wrist, rheumatoid, 56 F	10	0.1696
BRAINON01	brain, 26 M, NORM	4	0.1667
FIBRNGT01	GD23A fibroblasts, radiation 5 min	1	0.1667
MENTUN03	brain tumor, benign meningioma, 35 F, NORM	1	0.1667
CONNTUT01	skull tumor, chondroid chordoma, 30 F	6	0.1624
BRAINOT11	brain, right temporal, epilepsy, 5 M	5	0.1611
SCORNOT01	spinal cord, 71 M	8	0.1609
PGANNOT03	paraganglionic tumor, benign paraganglioma, 46 M	5	0.1555
COLNNOT13	colon, ascending, 28 M	5	0.1553
NGANNOT01	ganglioneuroma, 9 M	10	0.1552
BRSTNOT09	breast, 45 F, match to BRSTTUT08	6	0.1529
HEARFET01	heart, fetal M	6	0.1524
OVARNOM01	ovary, 49 F, WM	2	0.1504
BRSTTUT03	breast tumor, 58 F, match to BRSTNOT05	15	0.1479
LUNGNOT04	lung, 2 M	8	0.1464
PROSNOT15	prostate, 66 M, match to PROSTUT10	6	0.1448
COLNNOT05	colon, 40 M, match to COLNCRT01	5	0.1443
LIVSFEM02	liver/spleen, fetal M, NORM, WM	54	0.1423
SCORNON01	spinal cord, 71 M, NORM	1	0.1379
OLFENOM01	epithelium, olfactory, 35 F, WM	1	0.1330

FIGURE 13C

25/29

BSTMN02	brain stem, 72 M, NORM	4	0.1275
PROSN016	prostate, 68 M	5	0.1250
BSTMN01	brain stem, 72 M	1	0.1214
LUNGFEM01	lung, fetal, NORM, WM	8	0.1185
COLNNOT09	colon, 60 M	3	0.1171
PLACNOM01	placenta, fetal M, WM	2	0.1160
COCHFEM01	ear, cochlea, fetal, WM	1	0.1157
KIDNNOT05	kidney, neonatal F	7	0.1130
UTRSNOT06	uterus, myometrium, 50 F	4	0.1129
BRSTN02	breast, 55 F, match to BRSTTUT01	10	0.1109
LUNGNOT15	lung, 69 M, match to LUNGTUT03	4	0.1106
LUNGFET03	lung, fetal F	12	0.1096
PLACNOM03	placenta, fetal, NORM, WM	3	0.1088
BLADNOT03	bladder, 80 F, match to BLADTUT02	4	0.1084
BRAITUT01	brain tumor, oligoastrocytoma, 50 F	8	0.1076
PROSTUT10	prostate tumor, 66 M, match to PROSN015	4	0.1073
SPLNFET01	spleen, fetal	3	0.1057
BRAINOT10	brain, cerebellum, Alzheimer's, 74 M	3	0.1045
SCORN02	spinal cord, 71 M, NORM	3	0.1036
LIVRBCT01	liver, primary biliary cirrhosis	1	0.1032
BRSTTUT08	breast tumor, 45 F, match to BRSTN02	4	0.1015
BRAINOM01	brain, infant F, NORM, WM	22	0.0980
LATRTUT02	heart tumor, myoma, 43 M	7	0.0962
PGANNOT01	paraganglionic tumor, benign paraganglioma, 46 M	6	0.0960
BRAINOT14	brain, 40 F, match to BRAITUT12	3	0.0944
PLACNOM02	placenta, neonatal F, NORM, WM	17	0.0944
PANCDIT01	pancreas, juvenile IDDM, 15 M	2	0.0914
BRAINOT12	brain, right frontal, epilepsy, 5 M	3	0.0910

FIGURE 13D

26/29

RETNNOM01	retina, 55 M, NORM, WM	3	0.0908
BRAINOM02	brain, 55 M, NORM, WM	2	0.0907
CARDFEM01	heart, fetal, NORM, WM	8	0.0893
MUSCNOT01	muscle, skeletal	2	0.0890
TONGTUT01	tongue tumor, carcinoma, 36 M	3	0.0886
COLNTUT06	large intestine, cecal tumor, 45 F	3	0.0880
PROSNOT11	prostate, 28 M	3	0.0847
PROSTUT12	prostate tumor, 65 M, match to PROSNOT20	3	0.0838
BLADNOT04	bladder and seminal vesicle, 28 M	3	0.0833
COLNNOT22	colon, 56 F	3	0.0831
THYRNOT03	thyroid tumor, adenoma, 28 F	6	0.0830
PROSNOT19	prostate, 59 M	3	0.0815
PENITUT01	penis tumor, carcinoma, 64 M	3	0.0800
LUNGNOT10	lung, fetal M	3	0.0782
LUNGNOT14	lung, 47 M	3	0.0778
CERVNOT01	cervix, 35 F	4	0.0775
PANCTUT01	pancreatic tumor, 65 F, match to PANCNOT08	3	0.0773
MELANOM01	melanocytes, M, NORM, WM	8	0.0769
PROSNOT14	prostate, 60 M, match to PROSTUT08	3	0.0767
MENITUT03	brain tumor, benign meningioma, 35 F	3	0.0748
BRAINOT03	brain, 26 M	4	0.0742
GBLATUT01	gall bladder tumor, 78 F	3	0.0724
HIPONOT01	brain, hippocampus, 72 F	3	0.0717
MMLR1DT01	macrophages (adher PBMC), M/F, 24-hr MLR	3	0.0708
PROSNOT01	prostate, 78 M	2	0.0702
PITUNOT03	pituitary, 46 M	2	0.0697
PROSNOT06	prostate, 57 M, match to PROSTUT04	6	0.0685
ADRENOT03	adrenal gland, 17 M	2	0.0682
LVENNOT03	heart, left ventricle, 31 M	2	0.0677

FIGURE 13E

27/29

HIPONON01	brain, hippocampus, 72 F, NORM	2	0.0675
COLNTUT02	colon tumor, 75 M, match to COLNNOT01	3	0.0661
SPLNNOT02	spleen, 29 M	3	0.0659
OVARTUT01	ovarian tumor, 43 F, match to OVARNOT03	2	0.0646
COLNNOT16	colon, sigmoid, 62 M, match to COLNTUT03	3	0.0624
COLNNOT11	colon, 60 M	2	0.0617
BLADTUT02	bladder tumor, 80 F, match to BLADNOT03	2	0.0610
THYRNOT02	thyroid, hyperthyroidism, 16 F	2	0.0607
BRSTTUT02	breast tumor, 54 F, match to BRSTNOT03	2	0.0597
PROSTTUT04	prostate tumor, 57 M, match to PROSNOT06	5	0.0586
COLNNOT19	large intestine, cecum, 18 F	2	0.0585
PROSNON01	prostate, 28 M, NORM	2	0.0585
THYMNOT02	thymus, 3 M	3	0.0582
BEPINOT01	bronchial epithelium, primary cell line, 54 M	4	0.0577
BRSTTUT01	breast tumor, 55 F, match to BRSTNOT02	6	0.0567
LUNGTUT02	lung tumor, metastasis, 79 M, match to LUNGNOT03	3	0.0567
TESTNOT03	testis, 37 M	1	0.0558
BEPINON01	bronchial epithelium, primary cell line, 54 M, NORM	2	0.0547
PTHYTUM01	parathyroid tumor, adenoma, M/F, NORM, WM	2	0.0535
KIDNNOT09	kidney, fetal M	2	0.0534
BLADNOT05	bladder, 60 M, match to BLADTUT04	2	0.0528
BRSTNOM01	breast, F, NORM, WM	2	0.0528
DUODNOT02	small intestine, duodenum, 8 F	2	0.0525
BRAINNOT09	brain, fetal M	2	0.0524
LIVRTUT01	liver tumor, metastasis, 51 F	2	0.0518
COLNPOT01	colon polyp, 40 F	2	0.0513
PROSNOT18	prostate, hyperplasia, 58 M	2	0.0513

FIGURE 13F

SPLNNOT04	spleen, 2 M	4	0.0511
BLADTUT06	bladder tumor, carcinoma, 58 M	1	0.0507
OVARNOT03	ovary, 43 F, match to OVARUT01	3	0.0502
U937NOT01	U937 monocyte cell line, 37 M	1	0.0497
LUNGTUT03	lung tumor, 69 M, match to LUNGNOT15	3	0.0478
TESTNOT01	testis, 37 M	1	0.0478
PITUNOT01	pituitary, 16-70 M/F	1	0.0472
CORPNOT02	brain, corpus callosum, Alzheimer's, 74 M	3	0.0459
NERVMSM01	multiple sclerosis, 46 M, NORM, WM	2	0.0449
BMARNOR02	bone marrow, 16-70 M/F, RP	1	0.0442
PANCNOT01	pancreas, 29 M	2	0.0428
HUVENOB01	HUVEC endothelial cell line, control	1	0.0420
EOSIHET02	eosinophils, hypereosinophilia, 48 M	4	0.0419
THP1PLB02	THP-1 promonocyte cell line, treated PMA, LPS	1	0.0407
PANCTUT02	pancreatic tumor, carcinoma, 45 F	2	0.0403
LIVRNOT01	liver, 49 M	2	0.0397
COLNTUT03	colon tumor, 62 M, match to COLNNOT16	2	0.0392
CRBLNOT01	brain, cerebellum, 69 M	2	0.0391
ADENINB01	adenoid, inflamed, 3y	2	0.0381
TLYMNOR01	lymphocytes (non-adher PBMNC), 24 M, RP	1	0.0379
STOMTUT01	stomach tumor, 52 M, match to STOMNOT02	1	0.0368
BRAINOT04	brain, choroid plexus, hemorrhage, 44 M	1	0.0356
PROSNOT07	prostate, 69 M, match to PROSTUT05	1	0.0348
BRAITUT02	brain tumor, metastasis, 58 M	2	0.0340
TONSNOT01	tonsil, hyperplasia, 6 M	1	0.0339
PROSNOT20	prostate, hyperplasia, 65 M, match to PROSTUT12	1	0.0336
SINTBST01	small intestine, ileum, Crohn's, 18 F	2	0.0336
LNODNOT02	lymph nodes, 42 F	1	0.0335
HMC1NOT01	HMC-1 mast cell line, 52 F	1	0.0334

FIGURE 13G

29/29

MMLR3DT01	macrophages (adher PBMNC), M/F, 72-hr MLR	1	0.0332
SPLNFEM01	spleen, fetal, WM	1	0.0332
TBLYN0T01	T-B lymphoblast cell line, leukemia	1	0.0326
LPARN0T02	parotid gland, 70 M	1	0.0324
BRAITUT08	brain tumor, astrocytoma, 47 M	2	0.0293
PANCNOT05	pancreas, 2 M	2	0.0292
PROSTUT05	prostate tumor, 69 M, match to PROSN0T07	2	0.0290
DUODNOT01	small intestine, duodenum, 41 F	1	0.0287
STOMTUT02	stomach tumor, lymphoma, 68 F	1	0.0284
TESTTUT02	testicular tumor, 31 M	1	0.0278
SINTNOT13	small intestine, ileum, ulcerative colitis, 25 F	1	0.0275
HYPONOB01	hypothalamus, 16-75 M/F	1	0.0272
BMARNOT02	bone marrow, 16-70 M/F	1	0.0270
BRAINOM03	brain, 55 M, NORM, WM	1	0.0270
KIDNTUT01	kidney tumor, Wilms, 8m F	1	0.0267
PROSTUT08	prostate tumor, 60 M, match to PROSN0T14	1	0.0266
COLNNOT23	colon, 16 M	1	0.0264
BRAITUT13	brain tumor, meningioma, 68 M	1	0.0262
LEUKNOT03	white blood cells, 27 F	1	0.0262
BRAITUT07	brain tumor, left frontal, 32 M	1	0.0259
LIVSFEM03	liver/spleen, fetal M, NORM, WM	1	0.0256
STOMFET01	stomach, fetal F	1	0.0255
LIVRNOM01	liver, 49 M, WM	1	0.0254
TYLMNNOT02	lymphocytes (non-adher PBMNC), M/F	1	0.0254
TMLR3DT01	lymphocytes (non-adher PBMNC), M, 96-hr MLR	1	0.0229
HNT2NOT01	hNT2 cell line, teratocarcinoma, control	1	0.0173
UCMCL5T01	mononuclear cells, treated IL-5	1	0.0125

FIGURE 13H



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, 16/18, A61K 38/17	A3	(11) International Publication Number: WO 98/18822 (43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/US97/18717 (22) International Filing Date: 10 October 1997 (10.10.97) (30) Priority Data: 08/739,485 28 October 1996 (28.10.96) US (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GOLI, Surya, K. [IN/US]; 620 Iris Avenue #338, Sunnyvale, CA 94086 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). (74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).		(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 16 July 1998 (16.07.98)
(54) Title: NOVEL HUMAN LIM PROTEINS (57) Abstract <p>The present invention provides three human LIM proteins (designated individually as HLIM-1, HLIM-2, and HLIM-3, and collectively as HLIM) and polynucleotides which identify and encode HLIM. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HLIM and a method for producing HLIM. The invention also provides for use of HLIM and agonists, antibodies, or antagonists specifically binding HLIM, in the prevention and treatment of diseases associated with expression of HLIM. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HLIM for the treatment of diseases associated with the expression of HLIM. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HLIM.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/18717

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C07K16/18 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JAIN M.K. ET AL.: "Molecular cloning and characterization of SmLIM, a developmentally regulated LIM protein preferentially expressed in aortic smooth muscle cells" J. BIOL.CHEM., vol. 271, no. 17, April 1996, pages 10194-10199, XP002052120 cited in the application see abstract see figure 1 see figure 2	1-10,12, 16,17
A	---	11,13,14
	-/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

15 January 1998

Date of mailing of the international search report

27 -05- 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

INTERNATIONAL SEARCH REPORT

Application No
PCT/93 97/18717

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE : EMBL SEQUENCES EMBL, Heidelberg, FRG Accession No. U57646, 7 May 1996 WEISKIRCHEN R. ET AL.: "human cysteine-rich protein 2" XP002051947	1-10,12, 16,17
A	---	11,13,14
X	WANG X. ET AL.: "Human cysteine-rich protein" J. BIOL. CHEM., vol. 267, no. 13, May 1992, pages 9176-9184, XP002051944 cited in the application see the whole document	1-10,12, 16,17
A	---	11,13,14
X	ARBER S. ET AL.: "Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation" CELL, vol. 79, 21 October 1994, pages 221-231, XP002051945 cited in the application see the whole document See in particular page 226, column 1, lines 23 ff.	1-10,12, 16,17
A	-----	11,13,14

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 97/ 18717

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
See annex
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See annex

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-17

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-17

A substantially purified human LIM protein comprising the amino acid sequence of SEQ ID No. 1 or fragments thereof. An isolated and purified polynucleotide sequence encoding said human LIM protein, including the consensus defined in SEQ ID No 2 or variants thereof. A polynucleotide sequence which hybridizes under stringent conditions to said coding polynucleotide; a hybridization probe comprising said coding sequence or said hybridizing sequence. A method for detection of polynucleotides encoding the human LIM protein. A pharmaceutical composition comprising said LIM protein; a purified antibody directed against said protein; a purified agonist or antagonist which specifically binds to and modulates the activity of said protein. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of said pharmaceutical composition.

2. Claims: 18-34

Idem as subject 1 but limited to SEQ ID Nos. 3 and 4

3. Claims: 35-51

Idem as subject 1 but limited to SEQ ID Nos. 5 and 6.

Remark : Although claims 15 is directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, 16/18, A61K 38/17		A3	(11) International Publication Number: WO 98/18822
			(43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/US97/18717		(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 10 October 1997 (10.10.97)			
(30) Priority Data: 08/739,485 28 October 1996 (28.10.96) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/739,485 (CIP) Filed on 28 October 1996 (28.10.96)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		(88) Date of publication of the international search report: 16 July 1998 (16.07.98)	
(72) Inventors; and (75) Inventors/Applicants (for US only): GOLI, Surya, K. [IN/US]; 3311 Cantamar Court, San Jose, CA 95135 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US).			
(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).			
(54) Title: NOVEL HUMAN LIM PROTEINS			
(57) Abstract The present invention provides three human LIM proteins (designated individually as HLIM-1, HLIM-2, and HLIM-3, and collectively as HLIM) and polynucleotides which identify and encode HLIM. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HLIM and a method for producing HLIM. The invention also provides for use of HLIM and agonists, antibodies, or antagonists specifically binding HLIM, in the prevention and treatment of diseases associated with expression of HLIM. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HLIM for the treatment of diseases associated with the expression of HLIM. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HLIM.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		